| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
sNDA Submission example | REZZAYO (rezafungin for injection) prophylaxis of invasive fungal diseases in adults undergoing allogeneic HSCT | NDA | — | Subscribe to access the data. | Small Molecules | Infectious Diseases | |
sNDA Submission example | REZZAYO (rezafungin for injection) prophylaxis of invasive fungal diseases in adults undergoing allogeneic HSCT | NDA | — | Subscribe to access the data. | Small Molecules | Infectious Diseases | |
sNDA Submission example | REZZAYO (rezafungin for injection) prophylaxis of invasive fungal diseases in adults undergoing allogeneic HSCT | NDA | — | Subscribe to access the data. | Small Molecules | Infectious Diseases |
Recent Updates
Recently added Catalysts
CorMedix Inc.
$8.28
+0.08 (+0.98%)
C 52Pipeline Score Fair Value Biotech · Clinical
Market Cap
645.38 M
EPS
2.40
P/E Ratio
3.45 $
Value Trade
6.28 M
1.35 %
Week
8.95 %
1 Month
0.12 %
3 Month
17.11 %
6 Month
18.22 %
5 Year
-50.13 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
1.01 M
52 Week Range
6.13 - 14.96
% held by Insiders
7.88 %
% held by Institutions
57.08 %
Enterprise Value
388.69 M
Total Shares
77.94 M
Short %
22.68 %
Float Shares
70.94 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for CorMedix Inc.
540Total events
9Upcoming
151Tier-1 (high impact)
2012 – 2033Coverage
Upcoming catalysts 2
TBD
T2Product Launch
Subscribe to view catalyst details
TBD
T2Quarterly Update
Subscribe to view catalyst details
Event history 2
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▲Partnership / LicenseDefenCathApprovedCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | REZZAYO (rezafungin) | phase 3 data readout | Phase 3 | — | – | – | – |
2026-06-30 | REZZAYO (rezafungin) | phase 3 data readout | Phase 3 | — | – | – | – |
2026-06-30 | REZZAYO (rezafungin) | phase 3 data readout | Phase 3 | — | – | – | – |
Drug Pipeline Intelligence
C52
Pipeline Score $630M
Pipeline ValueFair Value
Valuation Signal14
Drugs Scored1.0x
rNPV / MCap Top 83%
Micro Cap (rank 160 of 933)
Percentile RankCorMedix Inc. carries a moderate pipeline score (52/100), with $1.6B risk-adjusted pipeline value, led by solithromycin in Nonalcoholic Steatohepatitis (Phase 2), across $79B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solithromycin Small molecule | Community-acquired Bacterial Pneumonia | Phase 3 | NCT01756339 | 62% | $414M | COMPLETED | 1,723 | - | - | Oct 1, 2014 | - | Mar 3, 2017 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
REZZAYO | prophylaxis of invasive fungal diseases in allogeneic hematopoietic stem cell transplantation patients | Phase 3 | 2026-04-27 | rezafungin fungal free survival: 60.7%; standard antimicrobial regimen fungal free survival: 59.0% Read More | CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients Read More | |
REZZAYO | prophylaxis of invasive fungal diseases in allogeneic hematopoietic stem cell transplantation patients | Phase 3 | 2026-04-27 | rezafungin fungal free survival: 60.7%; standard antimicrobial regimen fungal free survival: 59.0% Read More | CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients Read More | |
REZZAYO | prophylaxis of invasive fungal diseases in allogeneic hematopoietic stem cell transplantation patients | Phase 3 | 2026-04-27 | rezafungin fungal free survival: 60.7%; standard antimicrobial regimen fungal free survival: 59.0% Read More | CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CRMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CRMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CRMD▲ +14.6%on this news
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
CorMedix Therapeutics reported solid financial results for Q2 2026, with consolidated revenue reaching $101.9 million and net income of $26.0 million. The company anticipates an FDA submission for REZZAYO's expanded indication in the third quarter. Additionally, CorMedix has raised its full-year adjusted EBITDA guidance, reflecting confidence in its business outlook.
Read more →CRMDCorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
CorMedix Therapeutics will announce its second quarter financial results on August 13, 2026, before market opening. The company will also conduct a corporate update conference call at 8:30 AM ET. CorMedix is dedicated to developing therapeutic products for serious health conditions in the U.S.
Read more →CRMDU.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
CorMedix Therapeutics announced that the U.S. Court of Appeals upheld the validity of its MINOCIN® patents, affirming a previous district court ruling. The decision prevents Nexus Pharmaceuticals from marketing its generic version of minocycline until the patents expire. This ruling reinforces the importance of protecting pharmaceutical innovations and validates CorMedix's intellectual property efforts.
Read more →CRMDCormedix Therapeutics to Participate in two Upcoming Investor Conferences
CorMedix Therapeutics has announced its participation in the RBC Capital Markets Global Healthcare Conference and the Jefferies Global Healthcare Conference, both hosted in New York. The events will allow the company's management to engage in discussions through fireside chats and investor meetings. These conferences are set for May 19-20 and June 2-4, 2026, respectively, providing a platform for CorMedix to showcase its commitment to developing therapeutic products for severe medical conditions.
Read more →CRMD▲ +5.7%on this newsshared move
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
CorMedix Therapeutics reported a strong financial performance for the first quarter of 2026, posting a net revenue of $127.4 million, driven by solid sales of its DefenCath product. The company also increased its full-year 2026 revenue guidance, reflecting confidence in demand trends and ongoing clinical developments. A successful Phase III trial of REZZAYO could lead to a significant market opportunity in the coming years. However, rising operating expenses, primarily due to the Melinta acquisition, present a concern moving forward.
Read more →CRMDCorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
CorMedix Therapeutics will announce its first quarter financial results on May 14, 2026, before market opening. The company will also host a corporate update conference call at 8:30 AM ET. CorMedix is dedicated to developing therapeutic products for critical health conditions in the U.S.
Read more →CRMD▲ +5.4%on this news
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
CorMedix Therapeutics announced positive topline results from the Phase III ReSPECT trial, demonstrating that REZZAYO (rezafungin) is non-inferior to standard antimicrobial regimens for preventing invasive fungal diseases in allogeneic HSCT patients. The study showed favorable outcomes regarding safety and tolerability, with a significant market opportunity anticipated for the drug. The company plans to submit a supplemental New Drug Application to the FDA in the second half of 2026.
Read more →CRMDCorMedix to Participate in Needham Virtual Healthcare Conference
CorMedix Therapeutics will participate in the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026. Senior management will engage in a fireside chat and investor meetings. The company focuses on therapeutic products for life-threatening conditions, including their product DefenCath for preventing catheter-related infections. They also have ongoing clinical studies and a portfolio of anti-infective products.
Read more →CRMD▼ -11.5%on this news
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
CorMedix Inc. announced its financial results for Q4 and full-year 2025, reporting a net revenue of $128.6 million for the quarter and a pro forma total revenue of $401.3 million for the year. The company achieved a net income of $14.0 million in Q4, driven by strong sales of its product DefenCath. CorMedix also reiterated its guidance for 2026, aiming for net revenue between $300 and $320 million.
Read more →CRMDCorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026
CorMedix Inc. will announce its fourth quarter and full year 2025 financial results on March 5, 2026. The company will also host a corporate update conference call at 8:30 AM ET. CorMedix focuses on developing therapeutic products for life-threatening conditions and has a portfolio of anti-infective products following its acquisition of Melinta Therapeutics.
Read more →CRMDNOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTICS Corporate Presentation March 2026 CorMedix Therapeutics NOT FOR DISTRIBUTION WITHOUT THE PRIOR WRITTEN PERMISSION OF CORMEDIX THERAPEUTIC
CorMedix Therapeutics has presented a corporate overview for March 2026, highlighting its focus on innovative pharmaceutical products for institutional markets. The presentation includes forward-looking statements regarding the company's growth strategy, product pipeline, and financial projections. CorMedix anticipates revenue between $300 and $320 million in 2026 and has a specialty portfolio aimed at addressing significant market opportunities. The company emphasizes its leadership team's experience in driving commercial success and plans for further market developments.
Read more →CRMDCorMedix to Participate in Upcoming Investor Conferences
CorMedix Therapeutics (Nasdaq: CRMD) announced its participation in upcoming investor conferences in March. The company focuses on developing therapeutic products for life-threatening conditions and is commercializing DefenCath for preventing catheter-related bloodstream infections. Following its acquisition of Melinta Therapeutics, CorMedix is expanding its portfolio of anti-infective products and has ongoing clinical studies, including a Phase III study for REZZAYO.
Read more →CRMD▲ +5.3%on this news
CorMedix Therapeutics Announces Share Repurchase Program
CorMedix Therapeutics has announced a share repurchase program authorizing up to $75 million of its common stock. The program is set to run until December 31, 2027, and aims to return value to shareholders while maintaining financial flexibility for business investments. The company expects to start repurchasing shares in Q1 2026.
Read more →CRMDCorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026
CorMedix Therapeutics will host an in-person and virtual analyst day on February 10, 2026, in New York. The event will feature presentations on the company's pipeline and growth drivers, including updates on its Phase III programs for REZZAYO and DefenCath. Analysts and institutional investors can register for the event to gain insights into the company's strategies and market dynamics.
Read more →CRMDCorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
CorMedix Therapeutics will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company focuses on developing therapeutic products for life-threatening diseases and has a diverse portfolio, including DefenCath for preventing catheter-related infections. They are also advancing clinical studies for various products, with significant results expected in the near future.
Read more →CRMD▼ -32.8%on this newsshared move
CorMedix Therapeutics Announces Leadership and Board Updates
CorMedix Therapeutics has announced significant leadership updates, including CEO Joseph Todisco signing an extended contract and transitioning to Chairman of the Board. The company appointed Mike Seckler as the new EVP & Chief Commercial Officer, bringing extensive experience from various therapeutic areas. These changes are intended to strengthen the company and enhance its potential for future growth, particularly with a diversified product pipeline in development. The board's restructuring reflects the company’s ongoing evolution into a more robust commercial entity.
Read more →CRMD▼ -32.8%on this newsshared move
CorMedix THERAPEUTICS announces preliminary Fourth quarter and full year 2025 results and provides business updates Q4 2025 Unaudited Net Revenue of Approximately $127 million FY 2025 Unaudited Pro Forma Net Revenue of A
CorMedix Therapeutics has announced preliminary financial results for the fourth quarter and full year of 2025, highlighting an unaudited net revenue of approximately $127 million. The company saw its pro forma net revenue reach around $400 million, with an adjusted EBITDA expected between $77 million and $81 million. CEO Joseph Todisco expressed optimism regarding the company’s transformation into a multi-product entity, which is anticipated to strengthen shareholder value. CorMedix also has active ongoing clinical studies for its products, including DefenCath and REZZAYO, with future results expected.
Read more →CRMDCorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath
CorMedix Therapeutics announced positive interim results from its real-world evidence study of DefenCath, which reduces catheter-related bloodstream infections (CRBSI) in hemodialysis patients. The study, part of a collaboration with U.S. Renal Care, indicates a 72% reduction in CRBSI and a 70% decrease in related hospitalizations, suggesting significant benefits for patient care and healthcare costs. This data is expected to facilitate discussions with payers to expand access and reimbursement strategies. The study is ongoing, with continued evaluations of additional data points planned for the future.
Read more →CRMDCorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance
CorMedix Inc. reported strong financial results for Q3 2025, achieving net revenue of $104.3 million and a net income of $108.6 million. The company raised its FY 2025 pro forma net revenue guidance to a range of $390 to $410 million. However, operating expenses surged due to costs associated with the Melinta acquisition and increased R&D investments.
Read more →CRMDCorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
CorMedix Inc. has announced that it will report its third quarter financial results on November 12, 2025, before the market opens. The company, which specializes in therapies for critical diseases, is also hosting a corporate update conference call at 8:30 am ET. Following its acquisition of Melinta Therapeutics, CorMedix is commercializing a diverse portfolio of anti-infective products and continues work on its leading therapy, DefenCath, with ongoing clinical trials in pediatric populations. The company expects key results for some of its Phase III studies in the coming quarters.
Read more →CRMDCorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath
CorMedix Inc. announced that its product DefenCath has received an Innovative Technology designation from Vizient, highlighting its potential to enhance patient care. DefenCath, an antimicrobial catheter lock solution, has shown significant efficacy in reducing catheter-related bloodstream infections in patients undergoing hemodialysis. The designation underscores the product's importance in improving healthcare outcomes.
Read more →CRMD▲ +19.4%on this newsshared move
CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance
CorMedix Inc. announced preliminary unaudited results for Q3 2025, reporting net revenues exceeding $125 million, including over $85 million from DefenCath. The company has raised its full-year revenue guidance to at least $375 million and anticipates $30 million in operating synergies by the end of 2025. These results reflect the company's ongoing growth and strategic initiatives post-acquisition of Melinta Therapeutics.
Read more →CRMDCorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO
CorMedix has completed enrollment in its Phase III ReSPECT clinical trial for REZZAYO, aimed at preventing fungal infections in patients undergoing allogeneic blood and marrow transplantation. The trial evaluates the efficacy of rezafungin against standard antimicrobial regimens. Topline results are anticipated in the second quarter of 2026, which could lead to FDA approval for this indication.
Read more →CRMDCorMedix Announces Strategic Minority Investment in Talphera
CorMedix Inc. has announced a $5 million minority investment in Talphera, acquiring shares to support the development of Niyad, an anticoagulant currently in Phase 3 trials. This investment grants CorMedix exclusive negotiation rights for a potential acquisition of Talphera after the study results are announced. Talphera aims to use the funds to complete its ongoing clinical study and prepare for Niyad's market launch.
Read more →CRMDCorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team
CorMedix has successfully acquired Melinta Therapeutics, enhancing its commercial product portfolio with seven innovative drugs. The acquisition is expected to be accretive to earnings per share (EPS) and is projected to generate combined revenues of $325 to $350 million by 2025. The new leadership team aims to leverage synergies and drive growth in the hospital acute care sector.
Read more →CRMD▼ -9.5%on this news
CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings
CorMedix Inc. has announced its acquisition of Melinta Therapeutics for $300 million, enhancing its portfolio with six marketed infectious disease products. The deal includes potential regulatory milestones and royalties on sales. This acquisition is expected to strengthen CorMedix's position in the acute care market and drive future growth. The transaction is anticipated to close by September 1, 2025, pending regulatory approval.
Read more →CRMD▼ -9.5%on this newsshared move
CorMedix Inc. Reports second Quarter 2025 Financial Results and Provides Business Update Q2 2025 Net Revenue of $39.7mm; Net Income of $19.8mm; Adjusted EBITDA of $22.4mm Company Announces Acquisition of Melinta Therapeu
CorMedix Inc. reported strong second quarter 2025 financial results, with net revenue rising to $39.7 million and a net income of $19.8 million. This marks a significant turnaround from a loss during the same period last year. The company also announced its acquisition of Melinta Therapeutics, targeting a closing date in early September 2025. While CorMedix has ample cash reserves to support its operations, increasing operating expenses and integration risks related to the acquisition pose potential challenges.
Read more →CRMD▼ -16.4%on this news
CorMedix Inc. Announces Pricing of Public Offering of Common Stock
CorMedix Inc. has announced the successful pricing of an underwritten public offering of 6,604,507 shares of common stock, totaling approximately $85 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 15% of shares. Proceeds will be utilized for corporate purposes, including research costs and potential strategic deals. The offering is expected to close around June 30, 2025, pending customary conditions.
Read more →CRMDCorMedix Inc. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Berkeley Heights, NJ
CorMedix Inc. has announced its intention to offer $85 million in common stock as part of an underwritten public offering, exclusively conducted by the company. The proceeds from this offering will support general corporate purposes, including research and development for product candidates. Additionally, CorMedix recently launched its FDA-approved product, DefenCath, and is planning to expand its clinical studies, highlighting the company's growth strategy. However, the offering is contingent upon market conditions, which introduces potential uncertainty regarding its execution.
Read more →CRMD▲ +21.7%on this newsshared move
CorMedix Inc. announces customer IMPLEMENTATION Berkeley Heights, NJ
CorMedix Inc. announced that its Large Dialysis Organization customer has begun implementing its product DefenCath, aiming to reach a larger patient population than initially planned. This implementation is expected to contribute modest revenue beginning in June, with growth anticipated in the latter half of 2025. As a result, CorMedix has increased its sales guidance for the second quarter. The company maintains a focus on reducing catheter-related bloodstream infections with DefenCath.
Read more →CRMD▲ +21.7%on this newsshared move
CorMedix inc. Announces Customer Implementation
CorMedix Inc. announced the implementation of its product DefenCath with a Large Dialysis Organization customer, targeting at least 50% more patients than previously planned. The company has increased its second-quarter sales guidance from $31 million to a range of $35 million to $40 million due to this expansion. CEO Joseph Todisco expressed excitement regarding the broadened access to DefenCath, which is aimed at reducing catheter-related bloodstream infections. CorMedix's proactive approach and strong sales forecast illustrate its commitment to addressing critical health issues.
Read more →CRMDCorMedix Inc. To Participate In The Jefferies Global Healthcare Conference
CorMedix Inc. will participate in the Jefferies Global Healthcare Conference scheduled for June 3-5, 2025, in New York. The company focuses on developing therapeutic products for life-threatening conditions and has launched its lead product, DefenCath, following FDA approval in November 2023. CorMedix is furthering its efforts by entering clinical studies for Total Parenteral Nutrition patients and pediatric hemodialysis in 2025, signaling its commitment to expanding its therapeutic applications.
Read more →CRMDCorMedix Inc. to Participate in the RBC Global Healthcare Conference
CorMedix Inc. (Nasdaq: CRMD) will take part in the RBC Capital Markets Global Healthcare Conference on May 20-21, 2025. The company focuses on developing therapeutic products for life-threatening diseases. Its lead product, DefenCath, was approved by the FDA in November 2023 and has been launched in both inpatient and outpatient settings. Additionally, CorMedix plans to initiate clinical studies in targeted patient populations in 2025.
Read more →CRMD▲ +23.6%on this news
CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update Q1 2025 Net Revenue of $39.1mm; Adjusted EBITDA of $23.6mm Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley He
CorMedix Inc. announced its financial results for Q1 2025, highlighting net revenues of $39.1 million from sales of DefenCath and a net income of $20.6 million. This marks a significant improvement compared to a net loss of $14.5 million in Q1 2024. The company faces rising operating expenses, primarily due to increased research and development costs. Despite this, the overall financial outlook appears strong, supported by sufficient cash reserves to fund operations for at least another twelve months.
Read more →CRMDCorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025
CorMedix Inc. has announced it will report its first quarter 2025 financial results on May 6, 2025, before the market opens. The company will also host a corporate update conference call at 8:30 am ET on the same day. CorMedix focuses on developing therapeutic products for life-threatening conditions and has recently launched its product DefenCath in inpatient and outpatient settings. Upcoming clinical studies are set to target Total Parenteral Nutrition and Pediatric patients.
Read more →CRMD▲ +11.9%on this news
CorMedix Inc. announces preliminary FIRST quarter 2025 results and RAISES H1 2025 NET SALES GUIDANCE Q1 2025 Unaudited Net Revenue of $39.0 million Expected Q1 Adjusted EBITDA above $22.5 million Q1 2025 Cash and Cash Eq
CorMedix Inc. has announced its preliminary unaudited results for the first quarter of 2025, reporting significant financial metrics. The company projects net revenue of $39.0 million and adjusted EBITDA exceeding $22.5 million. Additionally, CorMedix has raised its net sales guidance for the first half of fiscal year 2025. The firm continues to focus on the commercialization of its lead product, DefenCath, which is aimed at preventing and treating life-threatening conditions.
Read more →CRMDCorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference
CorMedix Inc. is set to participate in the 24th Annual Needham Virtual Healthcare Conference scheduled for April 7-10, 2025. The company's management will engage in a fireside chat on April 8, 2025, at 2:15 PM EDT. CorMedix focuses on the development and commercialization of therapeutic products aimed at life-threatening conditions, including its lead product DefenCath, which was FDA-approved in November 2023 and commercially launched in 2024. The company is also initiating clinical studies for various patient populations in 2025.
Read more →CRMDCORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of CorMedix Stockholders and Encourages Investors to Contact the Firm
CorMedix Inc. is currently facing an investigation by Bragar Eagel & Squire, P.C. on behalf of stockholders, concerning potential violations of federal securities laws. This follows their recent earnings call where the company indicated that it anticipates net price erosion beginning in the second quarter of 2025. As a result of this news, the stock price has declined. Shareholders who suffered losses are encouraged to contact the law firm.
Read more →CRMD▼ -31.8%on this newsshared move
CORMEDIX INC. REPORTS fourth QUARTER and full year 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm C
CorMedix Inc. announced its financial results for Q4 and the full year of 2024, highlighting a net revenue of $31.2 million in the fourth quarter, driven largely by the successful launch of its product DefenCath. The company achieved a net income of $13.5 million for Q4, a significant improvement from a loss in the same period of the previous year. Despite the positive revenue growth, operating expenses rose, leading to a full-year net loss of $17.9 million, which the company attributed to increased commercial activities related to DefenCath. The management remains optimistic about growing the patient base in 2025.
Read more →CRMDCorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025
CorMedix Inc. has announced that it will report its financial results for the fourth quarter and full year of 2024, scheduled for March 25, 2025. The company will host a conference call at 8:30 AM ET on the same date to provide an update. CorMedix is focused on the commercialization of its lead product, DefenCath, and is set to begin clinical studies in 2025 targeting various patient populations. This announcement comes as the company continues its efforts in developing therapeutic solutions for life-threatening diseases.
Read more →CRMDCorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities
CorMedix Inc. has announced a collaboration with WSI PBG to promote its product DefenCath to the Department of Veterans Affairs and other federal facilities. This partnership aims to provide increased access to the therapy for around 40,000 veterans suffering from end-stage renal disease. The effort leverages WSI PBG's expertise in navigating federal healthcare systems to meet the specific needs of patients. CorMedix's CEO expressed optimism about this collaboration, highlighting its potential for enhancing health outcomes.
Read more →CRMD▲ +29.9%on this news· ran to +40% by day 3
ISSUED BY CORMEDIX INC., DATED JANUARY 7, 2025 E xhibit 99.1 CorMedix Inc. announces preliminary Fourth quarter 2024 results and provides business update Q4 2024 Unaudited Net Revenue of Approximately $31mm
CorMedix Inc. reported its preliminary unaudited fourth quarter 2024 results, revealing a net revenue of approximately $31 million and an adjusted EBITDA expected to exceed $12 million. The company successfully launched its lead product, DefenCath, across outpatient and inpatient settings, and is committed to expanding its use through an agreement with Syneos Health. CorMedix is also preparing to initiate clinical studies for DefenCath in new patient populations in 2025. CEO Joe Todisco expressed optimism about the company’s future performance and growth trajectory.
Read more →CRMD▲ +29.9%on this news· ran to +40% by day 3
CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update
CorMedix Inc. has announced its preliminary unaudited results for the fourth quarter and full year 2024, reporting significant net revenues and expected EBITDA. The company has revealed plans to expand its product DefenCath into inpatient settings and anticipates a substantial increase in orders from dialysis operators. A final clinical study protocol for DefenCath in Total Parenteral Nutrition has been submitted to the FDA, with enrollment expected to begin in 2025. Despite strong performance, increased operating expenses and the potential revisions of financial guidance remain future considerations.
Read more →CRMD▲ +9.2%on this news
CorMedix Inc. Added to Nasdaq Biotechnology Index
CorMedix Inc. has announced its inclusion in the Nasdaq Biotechnology Index, effective December 23, 2024. This index tracks biotechnology and pharmaceutical companies and is based on criteria such as market capitalization and trading volume. The addition signals a positive recognition of CorMedix's market position and performance. The company is also focused on the commercialization of its FDA-approved product, DefenCath, aimed at treating life-threatening conditions.
Read more →CRMDCorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products
CorMedix Inc. supports recent policy updates from CMS that enhance access to innovative drugs for hemodialysis patients. Starting January 2025, the updates will allow more ESRD patients participating in the Kidney Care Choices model to access drugs like CorMedix's DefenCath. This change aims to remove financial barriers, enabling improved patient care. CorMedix's CEO praised the updates as a significant step in aligning provider incentives with patient needs.
Read more →CRMDCorMedix Inc. to Participate in the Truist Securities BioPharma Symposium
CorMedix Inc. (Nasdaq: CRMD) has announced its participation in the upcoming Truist Securities BioPharma Symposium in New York City, scheduled for November 7, 2024. The company focuses on developing and commercializing therapeutic products for serious health conditions, specifically highlighting its FDA-approved product, DefenCath, which launched in 2024. CorMedix aims to expand the use of DefenCath as a catheter lock solution in various patient populations. This engagement at the symposium may provide an opportunity for greater exposure and networking within the biopharma industry.
Read more →CRMD▼ -22.5%on this newsshared move
CorMedix Inc. Reports THIRD Quarter AND NINE MONTH 2024 Financial Results and Provides Business Update Q3 2024 Net Revenue of $11.5 million Commercializing DefenCath with Four of Top Five US Dialysis Providers Conference
CorMedix Inc. announced its financial results for Q3 2024, reporting net revenue of $11.5 million from the sales of DefenCath. The company has achieved patient access in approximately 60% of outpatient dialysis clinics in the US, indicating a positive market reception. CorMedix reduced its net loss from the previous year, although operating expenses rose by 34%, continuing to drive overall losses. The company is optimistic about upcoming clinical initiatives aimed at expanding DefenCath's medical indications.
Read more →CRMDCorMedix Inc. Announces New Data at ASN Kidney Week 2024
CorMedix Inc. presented new hospital admission and health economic data at the ASN Kidney Week 2024. The retrospective analysis of 91,448 patients highlighted that 25% were hospitalized for bloodstream infections, revealing critical demographics and outcomes. With a median hospitalization cost of $157,000 and an in-hospital mortality rate of 10.3%, the findings stress the urgent need for improved management strategies for catheter-related bloodstream infections. CorMedix's CEO emphasized the need for intervention to lessen the incidence and financial toll of these infections.
Read more →CRMDCorMedix Inc. to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on October 30, 2024
CorMedix Inc. will release its third quarter 2024 financial results on October 30, 2024. The announcement includes a corporate update call scheduled for 8:30 am EDT on the same day. The company is focused on the commercialization of its lead product, DefenCath, which received FDA approval in November 2023 and has been launched in various healthcare settings. This proactive communication reflects the company's commitment to informing stakeholders about its financial performance and product development.
Read more →CRMD▲ +5.5%on this news
CorMedix Announces New Commercial Agreement with Mid-Sized Dialysis Operator
CorMedix Inc. has announced a new commercial supply contract with a top-five mid-sized dialysis operator for its product, DefenCath, aimed at adult patients undergoing hemodialysis. This agreement allows DefenCath to be supplied to more than 200 outpatient clinics across the U.S., thereby increasing patient access. The product, approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs, has been successfully launched in both inpatient and outpatient settings. Shipments under this contract are expected to commence in the fourth quarter of 2024.
Read more →CRMDCorMedix Inc. Announces New Commercial Agreement
CorMedix Inc. has entered into a new commercial supply agreement for DefenCath with a leading mid-sized dialysis operator, enabling access to the drug in numerous outpatient clinics across the U.S. The drug, which received NDA approval in November 2023 and was launched in inpatient settings earlier this year, is indicated for use in adult patients undergoing hemodialysis. Shipments under the new agreement are expected to commence in the early fourth quarter of 2024. The announcement comes as the company continues to expand its partnerships in the dialysis sector.
Read more →CRMDCorMedix Inc. to Present at the Cantor Global Healthcare Conference
CorMedix Inc. will participate in the 2024 Cantor Global Healthcare Conference located in New York from September 17 to 19. The company's management plans to engage in a fireside chat and hold one-on-one investor meetings during the event. CorMedix has recently launched its lead product, DefenCath, which received FDA approval in November 2023 and aims to broaden its therapeutic applications. This participation underscores CorMedix's commitment to advancing its commercial strategies in the biopharmaceutical market.
Read more →CRMD▲ +30.2%on this news
CorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2024 Financial Results and Provides Business Update Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ
CorMedix Inc. reported its financial results for the second quarter and six months ended June 30, 2024. The company has launched its lead product, DefenCath, in both inpatient and outpatient settings, with positive early revenue indications. Despite a net loss increase to $14.2 million for Q2, driven largely by higher operating expenses, CorMedix continues to focus on expanding the product's indications. They reported cash and short-term investments of $45.6 million as of June 30, 2024, which is believed to be sufficient for at least twelve months of operations.
Read more →CRMDCorMedix Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 14, 2024
CorMedix Inc. plans to report its financial results for the second quarter of 2024 on August 14, 2024. The company will also host a conference call to provide a corporate update. Recently, CorMedix launched its lead product, DefenCath, which received FDA approval in November 2023 and is aimed at life-threatening conditions. The dual launch in inpatient and outpatient settings reflects advancements in their commercialization strategy.
Read more →CRMDCorMedix Inc. Announces Outpatient Availability of DefenCath
CorMedix Inc. (Nasdaq: CRMD) has initiated the outpatient availability of its product DefenCath® (taurolidine and heparin) for dialysis centers and vascular clinics. This launch follows the outpatient reimbursement guidelines set by CMS effective July 1st. DefenCath is the only FDA-approved antimicrobial catheter lock solution and aims to reduce catheter-related bloodstream infections in patients with kidney failure. CorMedix had previously launched DefenCath in inpatient settings in April 2024, and anticipates increased access as more customer contracts are secured.
Read more →CRMDCorMedix Inc. Receives FDA Feedback on Potential Label Expansion
CorMedix Inc. has received supportive feedback from the FDA regarding its plans to expand indications for DefenCath to prevent Central Line Associated Blood Stream Infections in adult TPN patients. The company is preparing to submit a complete clinical protocol to the FDA by the third quarter of 2024, aiming to align further and initiate the program by the end of the year. The FDA has also mandated a study in pediatric hemodialysis patients under the Pediatric Research Equity Act. With estimates showing a high rate of CLABSI in TPN patients, CorMedix anticipates a significant opportunity in this market.
Read more →CRMDCorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath
CorMedix Inc. has announced that its product DefenCath® has been granted pass-through status by the Center for Medicare & Medicaid Services (CMS) under the Out-Patient Prospective Payment System (OPPS). This status enables separate Medicare reimbursements for DefenCath when used in outpatient surgical settings for at least two years. CorMedix plans to commercially launch DefenCath for outpatient use in July 2024, following its earlier success in inpatient settings. DefenCath is indicated for reducing catheter-related bloodstream infections in patients undergoing hemodialysis through central venous catheters.
Read more →CRMDCorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider
CorMedix Inc. has announced a significant commercial supply contract with a leading midsized dialysis provider for its product DefenCath, aimed at reducing catheter-related bloodstream infections. Following FDA approval granted on November 15, 2023, CorMedix has already begun the commercialization of DefenCath in inpatient settings as of April 2024 and expects to launch in outpatient clinics in July 2024. This agreement will enhance patient access in over 500 national dialysis facilities, aligning with the company's commitment to infection reduction.
Read more →CRMDCorMedix Inc. to Participate in Two Upcoming Investor Conferences
CorMedix Inc. has announced its participation in two key investor conferences: the JMP Securities Life Sciences Conference on May 14, 2024, and the RBC Capital Markets Global Healthcare Conference on May 15, 2024. The company aims to highlight its recently launched product, DefenCath, which was approved by the FDA in November 2023. CorMedix is planning to expand the use of DefenCath in outpatient settings later this summer.
Read more →CRMD▼ -5.2%on this newsshared move
CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ
CorMedix Inc. has reported its financial results for the first quarter of 2024, highlighting a net loss of $14.5 million, up from $10.6 million the previous year. The company has made strides in transitioning to a commercial stage, with growing interest in its product DefenCath for hemodialysis patients. CorMedix plans to launch DefenCath in outpatient settings by July 2024. Despite the increase in net loss, the company maintains sufficient cash resources to fund operations for at least the next twelve months.
Read more →CRMDCorMedix Inc. To Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024
CorMedix Inc. will report its first quarter financial results for 2024 on May 9, 2024. The company will also host a corporate update conference call at 8:30 AM ET. Following the FDA approval of its lead product, DefenCath, in November 2023, CorMedix launched it in inpatient settings in April 2024. The outpatient launch is expected in July 2024, with plans to explore additional uses for DefenCath.
Read more →CRMDCorMedix Inc. Announces CMS Grants TDAPA to DefenCath
CorMedix Inc. has announced that the Center for Medicare & Medicaid Services (CMS) has granted transitional drug add-on payment (TDAPA) eligibility to its product DefenCath. This eligibility, effective July 1, 2024, is significant for the outpatient reimbursement of the anti-infective solution designed to reduce catheter-related bloodstream infections in patients undergoing chronic hemodialysis. This move is part of CorMedix's strategy to launch DefenCath in outpatient settings, building on its recent FDA approval in November 2023 and inpatient launch in April 2024.
Read more →CRMD▼ -7.9%on this news
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath (Taurolidine and Heparin)
CorMedix Inc. has announced the commercial availability of its product, DefenCath, which is a catheter lock solution approved by the FDA for use in U.S. inpatient settings. The product aims to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure undergoing hemodialysis. The company plans to expand DefenCath's availability to outpatient settings by July 2024, dependent on CMS approval for reimbursement. The product's use is limited to specific patient populations, necessitating careful consideration of patient eligibility.
Read more →CRMD▲ +21%on this newsshared move
CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference
CorMedix Inc. has announced that two abstracts have been accepted for presentation at the upcoming Society for Healthcare Epidemiology of America conference in Houston, Texas. The first abstract showcases taurolidine's effectiveness against various bacteria linked to catheter-related bloodstream infections, while the second highlights the severe impacts of hospital-acquired bloodstream infections in patients on hemodialysis. CorMedix is preparing for the commercial launch of its lead product, DefenCath, anticipated in April and July 2024 for inpatient and outpatient settings, respectively.
Read more →CRMDCorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC
CorMedix Inc. has announced a five-year commercial supply contract with ARC Dialysis for the distribution of its FDA-approved product, DefenCath. Set to begin commercialization in inpatient settings on April 15, 2024, DefenCath aims to improve patient safety by preventing infections in hemodialysis patients. The partnership reflects CorMedix's commitment to innovative solutions in healthcare. ARC Dialysis is recognized for its focus on superior patient care and has integrated DefenCath into its strategy of leveraging innovative technologies.
Read more →CRMDCorMedix Inc. to Present at the Needham Annual Healthcare Conference
CorMedix Inc. announced its participation at the Needham 23rd Annual Healthcare Conference to be held virtually from April 8 to 11, 2024. The company focuses on developing and commercializing therapeutic products, particularly its lead product, DefenCath, which received FDA approval in November 2023. CorMedix plans to launch DefenCath in inpatient settings by April 2024, followed by outpatient settings in July 2024, contingent on timely implementation of TDAPA. This engagement represents a strategic opportunity for the company to connect with investors regarding its latest developments.
Read more →CRMDCORMEDIX INC. REPORTS fourth QUARTER and full year 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ
CorMedix Inc. has announced its financial results for the fourth quarter and full year of 2023. The company reported a net loss of $14.8 million for Q4 and a total of $46.3 million for the year, with operating expenses significantly increasing due to pre-launch activities for their product, DefenCath. Despite these losses, CEO Joe Todisco expressed optimism regarding the upcoming commercial launch of DefenCath, which aims to reduce catheter-related bloodstream infections in hemodialysis patients. A conference call was scheduled to discuss these results and the company's future plans further.
Read more →CRMDCorMedix Inc. to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 12, 2024
CorMedix Inc. announced it will report its financial results for Q4 and full year 2023 on March 12, 2024. The company will hold a corporate update conference call the same day. Notably, CorMedix gained FDA approval for its lead product, DefenCath, designed to reduce catheter-related infections. The product is set to launch on April 15, 2024, and the company is exploring further applications for DefenCath.
Read more →CRMD▼ -6.3%on this news
CORMEDIX INC. announces commercial AND REiMBURSEMENT updates Berkeley Heights, NJ
CorMedix Inc. has announced positive updates regarding its business and the anticipated launch of its lead product, DefenCath. The company received a timely decision from CMS, which facilitates the commercialization process, and has reported strong interest from both inpatient facilities and outpatient dialysis providers. With DefenCath approved by the FDA and an initial launch date set for April 15, 2024, CorMedix is optimistic about its market entry. However, the company cautions that several forward-looking statements involve inherent risks and uncertainties.
Read more →CRMD▲ +6.5%on this news
CorMedix Inc. Announces Commercial and Operational Updates
CorMedix Inc. has announced updates regarding its lead product DefenCath, which is targeted to prevent bloodstream infections in hemodialysis patients. The company has submitted an HCPCS application for a J-Code to the CMS and is currently under review. Commercial availability is estimated for April 2024 in the inpatient setting while the outpatient launch depends on reimbursement determinations. The CEO reported strong interest from various health systems and plans to establish a sales team ahead of the product's launch.
Read more →CRMDCorMedix Inc. Announces Appointment of Chief Legal Officer
CorMedix Inc. has announced the appointment of Beth Zelnick Kaufman as its new Chief Legal Officer, effective December 12, 2023. Kaufman brings over two decades of experience in the life sciences sector, having previously held key legal positions at Akorn Pharmaceuticals and Amneal Pharmaceuticals. Her expertise is expected to support the company's transition towards commercial operations, particularly with the upcoming launch of their FDA-approved product, DefenCath. Former General Counsel Dr. Phoebe Mounts will be leaving the company to pursue new opportunities.
Read more →CRMD▲ +6.3%on this news
CorMedix Inc. Announces Partnership With The Leapfrog Group
CorMedix Inc. has announced its partnership with The Leapfrog Group to improve patient safety and infection prevention. As part of this collaboration, CorMedix will engage with Leapfrog's Partners Advisory Committee to influence industry standards and practices. The move underscores CorMedix's commitment to reducing catheter-related bloodstream infections through its FDA-approved product, DefenCath, which targets a specific patient population. This partnership aims to elevate healthcare quality standards across the United States and promote shared accountability in patient care.
Read more →CRMD▲ +6.4%on this news· ran to +21% by day 1
CORMEDIX INC. ANNOUNCES FDA APProval of Defencath To reduce the incidence of catheter-related bloodstream infections in adult hemodialysis patients - First and only FDA-approved antimicrobial catheter lock solution in th
CorMedix Inc. announced FDA approval of DefenCath, an antimicrobial catheter lock solution aimed at reducing catheter-related bloodstream infections (CRBSIs) in adult hemodialysis patients. This marked the first such approval in the U.S., following a successful Phase 3 clinical trial that showed a 71% reduction in CRBSIs. The drug is expected to become available in early 2024, providing a new treatment option for patients who are at risk of life-threatening infections associated with central venous catheters.
Read more →CRMDCORMEDIX INC. REPORTS THIRD QUARTER AND NINE MONTH 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ
CorMedix Inc. reported its financial results for the third quarter and nine months ending September 30, 2023, highlighting a net loss attributed to increased operating expenses linked to pre-launch activities for its product, DefenCath. The net loss increased from the previous year, reflecting a 50% rise in operating expenses. Despite this, the CEO expressed confidence due to the successful outcomes of preapproval inspections and progress towards commercial readiness. A conference call is scheduled to discuss these developments further.
Read more →CRMDCorMedix Inc. to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on November 14, 2023
CorMedix Inc. announced that it will report its third quarter 2023 financial results on November 14, followed by a corporate update conference call. The company is focused on its lead product, DefenCath, which aims to prevent bloodstream infections in hemodialysis patients and has been recognized by the FDA for its potential. The NDA for DefenCath has had regulatory challenges, including a second Complete Response Letter from the FDA in August 2022, but was resubmitted and is pending action. The company's future plans include developing additional therapies targeting rare pediatric cancers.
Read more →CRMDCorMedix Inc. Announces Abstract Presentation at Upcoming IDWeek Conference
CorMedix Inc. has announced that an abstract showcasing data on the in vitro activity of taurolidine against Candida auris has been accepted for presentation at the IDWeek 2023 conference. The data indicate taurolidine's effectiveness against all C. auris strains, suggesting its potential use in preventing catheter-related bloodstream infections. This announcement coincides with CorMedix's ongoing efforts to gain FDA approval for its lead product, DefenCath, which is designed to prevent such infections. However, the company faces challenges, including recent FDA communications regarding manufacturing issues and the need for further regulatory compliance.
Read more →CRMDCorMedix Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
CorMedix Inc. (Nasdaq: CRMD) is set to present at the Cantor Fitzgerald Global Healthcare Conference from September 26-28, 2023, showcasing its focus on therapeutic products. The company is particularly emphasizing DefenCath®, a non-antibiotic antimicrobial solution aimed at preventing bloodstream infections in hemodialysis patients. Although the FDA has accepted its New Drug Application for filing, CorMedix faces regulatory hurdles, including a second Complete Response Letter concerning deficiencies at its manufacturing partners. Nevertheless, the company continues to work on expanding the application of DefenCath and other innovative therapies.
Read more →CRMDCorMedix Inc. Announces Publication of Phase 3 LOCK IT-100 Study Data in the Clinical Journal of The American Society of Nephrology
CorMedix Inc. announced the publication of the Phase 3 LOCK IT-100 study results in the Clinical Journal of the American Society of Nephrology. The study showed DefenCath significantly reduces the risk of Catheter Related Bloodstream Infections in patients undergoing hemodialysis. Following the positive results, CorMedix has resubmitted its New Drug Application (NDA) for DefenCath, which has been accepted for FDA filing with a target decision date of November 15, 2023. The company aims to address a critical medical need while also planning future studies in pediatric populations.
Read more →CRMDCorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference
CorMedix Inc. will present at the H.C. Wainwright Global Investment Conference on September 13, 2023, highlighting its biopharmaceutical endeavors. The company's lead product, DefenCath, designed to prevent bloodstream infections in hemodialysis patients, has received Fast Track and Qualified Infectious Disease Product designations from the FDA. Despite these advancements, CorMedix faces regulatory hurdles, including a second Complete Response Letter regarding manufacturing deficiencies. The company is also looking to expand the use of DefenCath in pediatric populations and other applications.
Read more →CRMDCorMedix Inc. Announces Issuance of U.S. Patent Covering Lead Product Defencath
CorMedix Inc. has announced that the USPTO has issued U.S. Patent No. 11,738,120 for its lead product, DefenCath, which addresses infection prevention in central venous catheters. This patent enhances the company's intellectual property protection, extending it to 2042. DefenCath may qualify for 10.5 years of market exclusivity following FDA approval, leveraging its Fast Track and QIDP designations. However, CorMedix faces challenges, including a prior FDA Complete Response Letter regarding manufacturing concerns.
Read more →CRMD▲ +7.9%on this news
CorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2023 Financial Results and Provides Business Update Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ
CorMedix Inc. reported its financial results for the second quarter and six months ending June 30, 2023, highlighting a net loss of $11.3 million in Q2, an increase from the previous year. The company is focusing on achieving FDA approval for its product DefenCath, which aims to reduce infection risks in hemodialysis patients. Despite financial losses, CorMedix is optimistic about its future, having successfully raised funds and positioned itself well for operational execution ahead of the FDA's action date in November.
Read more →CRMDCorMedix Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 8, 2023
CorMedix Inc. plans to report its second quarter financial results on August 8, 2023, before market opening and will hold a corporate update call. The company is focused on its lead product DefenCath, which aims to prevent life-threatening bloodstream infections in hemodialysis patients. Following a second Complete Response Letter from the FDA, CorMedix resubmitted its New Drug Application for DefenCath after receiving guidance from the agency. While the FDA has accepted the resubmission, recent manufacturing concerns indicate potential delays in the approval process.
Read more →CRMD▼ -22.3%on this news
CorMedix Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Pre-Funded Warrants
CorMedix Inc. has priced its public offering of 7,500,000 shares of common stock at $4.00 per share, raising a total of approximately $40 million. The company plans to use the proceeds to support general corporate needs, R&D, and commercialization of its lead product, DefenCath. Recently, the NDA for DefenCath was accepted by the FDA after previous manufacturing issues were addressed. Despite positive developments, there are noted risks including FDA-related scrutiny and market conditions.
Read more →CRMDCORMEDIX INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS Berkeley Heights, NJ
CorMedix Inc. has announced a proposed public offering of common stock and pre-funded warrants to raise funds for corporate purposes, including commercialization and R&D efforts for its lead antimicrobial product, DefenCath. The offering is subject to market conditions, and the company has faced regulatory hurdles, including a second Complete Response Letter from the FDA. Despite these challenges, CorMedix aims to enhance its financial resources and continue developing its product pipeline, which includes research into therapies for rare pediatric cancers.
Read more →CRMD▲ +5.6%on this news
CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE OF RESUBMISSION OF NEW DRUG APPLICATION FOR DEFENCATH Berkeley Heights, NJ
CorMedix Inc. announced that the FDA has accepted the resubmission of the New Drug Application (NDA) for its product DefenCath, which aims to reduce catheter-related bloodstream infections in patients undergoing hemodialysis. The FDA's acceptance is classified as a complete response, with a six-month review period until the target action date of November 15, 2023. DefenCath has received Fast Track and Qualified Infectious Disease Product designations, enhancing its marketing exclusivity prospects. However, the company previously faced challenges with a complete response letter regarding manufacturing issues, which adds an element of risk as it prepares for potential commercial launch.
Read more →CRMD▼ -5.1%on this newsshared move
Cormedix Inc. Announces Strategic Initiative With Boston Medical Center to Reduce Health Disparities in Patients at Risk for Bloodstream Infections
CorMedix Inc. has launched a strategic collaboration with Boston Medical Center to address health disparities linked to bloodstream infections in dialysis patients. The initiative focuses on evaluating a novel antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections, particularly in marginalized communities. This partnership aims to assess healthcare inequities and enhance patient outcomes, emphasizing equitable care in the treatment of chronic conditions. Despite the positive impact anticipated, the company faces hurdles, including regulatory challenges with their product's NDA and concerns about supplier relationships.
Read more →CRMDCormedix Inc. To Present At The Jefferies Healthcare Conference
Cormedix Inc. will present at the upcoming Jefferies Healthcare Conference, focusing on its lead product, DefenCath. This novel antimicrobial solution aims to prevent bloodstream infections in hemodialysis patients and has been granted Fast Track designation by the FDA. Despite recent regulatory hurdles, including a second Complete Response Letter from the FDA, CorMedix continues to pursue its NDA resubmission and intends to expand DefenCath's indications. The company also plans to explore taurolidine-based therapies for rare pediatric cancers.
Read more →CRMD▼ -13.4%on this news
CorMedix Inc. ANNOUNCES RESUBMISSION Of New drug application for defencath Berkeley Heights, NJ
CorMedix Inc. has announced the resubmission of its New Drug Application (NDA) for DefenCath to the FDA, which has been acknowledged for processing. The resubmission reflects the company's regulatory efforts and aims for approval in 2023 to address bloodstream infection risks in hemodialysis patients. DefenCath is recognized as a Fast Track and Qualified Infectious Disease Product, offering potential additional marketing exclusivity upon approval. However, the company faces challenges from previous FDA feedback and financial uncertainties impacting future development.
Read more →CRMDCorMedix Inc. Reports First Quarter 2023 Financial Results and Provides Business Update Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ
CorMedix Inc. reported its financial results for Q1 2023, indicating a net loss of $10.6 million, higher than the previous year. The company announced that it is ready to resubmit the NDA for its product DefenCath, which aims to prevent infections in hemodialysis patients, to the FDA. With a focus on a potential commercial launch in early 2024, CorMedix also highlighted the adequacy of its financial resources to sustain operations at least through the first half of 2024. The company's regulatory efforts continue amidst challenges posed by increased operating expenses and recent FDA feedback.
Read more →CRMD▲ +6.1%on this news
CorMedix Inc. To Report First Quarter 2023 Financial Results and Provide a Corporate Update on May 15, 2023
CorMedix Inc. announced it will report its financial results for the first quarter of 2023 on May 15, 2023, followed by a corporate update conference call. The company focuses on its lead product, DefenCath™, which aims to prevent bloodstream infections associated with hemodialysis. Despite receiving FDA Fast Track and QIDP designations, CorMedix faced regulatory challenges with a second Complete Response Letter regarding manufacturing deficiencies. The company plans to resubmit its New Drug Application by mid-May 2023 and is also exploring further applications of DefenCath and developing taurolidine-based therapies for pediatric cancers.
Read more →CRMDCorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCath
CorMedix Inc. has announced the allowance of its patent application for DefenCath, a catheter lock solution aimed at preventing infections in patients. This development underscores the product's innovative formulation, and the company intends to resubmit its New Drug Application (NDA) to the FDA by mid-May. CorMedix expects to eventually receive additional patent protection and statutory marketing exclusivity upon approval. However, the company faces challenges from a prior Complete Response Letter regarding manufacturing issues that could impact approval timelines.
Read more →CRMD▼ -9%on this newsshared move
CORMEDIX INC. ANNOUNCES REGULATORY, MANUFACTURING AND REIMBURSEMENT UPDATES Berkeley Heights, NJ
CorMedix Inc. announced plans to resubmit its New Drug Application for DefenCath following a recent Type A meeting with the FDA. The company received a proposed NTAP for DefenCath, potentially providing significant reimbursement to hospitals, contingent on FDA approval before July 2024. The announcement is tempered by previous challenges, including a Complete Response Letter from the FDA due to manufacturing deficiencies, which they have begun addressing by qualifying new suppliers. CEO Joe Todisco expressed optimism about the upcoming submissions and the potential impact of DefenCath in preventing infections in hemodialysis patients.
Read more →CRMDCORMEDIX INC. ANNOUNCES APPOINTMENT OF ROBERT A. STEWART TO ITS BOARD OF DIRECTORS Berkeley Heights, NJ
CorMedix Inc. appointed Robert A. Stewart to its Board of Directors, expanding the board to eight members. Stewart brings significant experience in the pharmaceutical industry, which is anticipated to aid CorMedix's transition to a commercial organization. The company is focused on its lead product, DefenCath, designed to prevent life-threatening infections associated with central venous catheters. However, FDA Complete Response Letters indicate challenges with NDA approval due to manufacturing issues and deficiencies that must be resolved.
Read more →CRMD▲ +13.1%on this news
DATED MARCH 30, 2023 Exhbit 99.1 CORMEDIX INC. REPORTS fourth QUARTER and full year 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley
CorMedix Inc. reported its fourth quarter and full year 2022 financial results, indicating a net loss increase from the previous year. The company has been granted a Type A meeting by the FDA to discuss guidance for its product DefenCath, aimed at preventing infections in hemodialysis patients. Although progress has been made in addressing manufacturing deficiencies, CorMedix faces challenges including rising operating expenses and regulatory hurdles. The company aims for FDA approval of DefenCath in 2023, while also ensuring sufficient resources for continued operations.
Read more →CRMD▲ +13.1%on this news
CorMedix Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
CorMedix Inc. reported its financial results for Q4 and full year 2022, highlighting a net loss of $8.2 million for Q4 and $29.7 million for the year. The company has made significant progress toward FDA approval for its product DefenCath, including completing corrective actions at its manufacturing partners. Despite increasing net losses due to pre-launch costs, CorMedix maintains a strong cash position and is preparing for commercialization. The company has also updated its leadership team to better align resources for potential launches in the near future.
Read more →CRMDCormedix Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results and Provide a Corporate Update on March 30, 2023
CorMedix Inc. is set to disclose its financial results for the fourth quarter and fiscal year 2022 on March 30, 2023. The company focuses on developing therapies, particularly DefenCath, aimed at preventing infections in patients with central venous catheters. Despite receiving FDA designations for DefenCath, the company faces delays in NDA approval due to manufacturing deficiencies highlighted in Complete Response Letters. Meanwhile, CorMedix is working to address these issues and expand its product applications.
Read more →CRMDCORMEDIX INC. ANNOUNCES REGULATORY AND MANUFACTURING UPDATES Berkeley Heights, NJ
CorMedix Inc. has announced updates regarding its regulatory compliance efforts and manufacturing plans for its product DefenCath, which is under FDA review. The company is progressing with remediation activities at its contract manufacturing organization and seeks guidance from the FDA via a Type A meeting. CorMedix plans to provide updates on its resubmission timelines for its New Drug Application, with a focus on potential pathways. Additionally, the firm has received Fast Track and QIDP designations from the FDA for DefenCath, which is aimed at preventing life-threatening infections in patients undergoing hemodialysis.
Read more →CRMDCorMedix Inc. Announces Promotions in Commercial and Tech Ops
CorMedix Inc. has announced significant promotions within its leadership, including Erin Mistry to Chief Commercial Officer and Tushar Mukherjee to Head of Technical Operations. These changes are aimed at enhancing the company's readiness for commercializing its lead product, DefenCath, an antibacterial solution. Despite positive FDA designations for DefenCath, the company faces challenges with its New Drug Application (NDA) due to deficiencies identified during FDA inspections of its manufacturing partners. CorMedix is taking steps to resolve these issues while also working on further developing its product pipeline.
Read more →CRMD▼ -9.6%on this news
Cormedix Inc. Announces Presentation at Conference Showing Mortality Risk and Complications in Patients Experiencing Catheter Related Blood Stream Infections
BERKELEY HEIGHTS, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the abs
Read more →CRMD▲ +9.2%on this news· ran to +31% by day 1
CORMEDIX INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ
INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Call Scheduled for Today at 8:30 a.m. Eastern Time NJ - November 10, 2022 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products f
Read more →CRMDCorMedix Inc. Announces CMS Revision to NTAP Reimbursement of DefenCath
BERKELEY HEIGHTS, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that th
Read more →CRMDCorMedix Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10
BERKELEY HEIGHTS, N.J. , Nov. 02, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that i
Read more →CRMDCorMedix Inc. Announces Abstract Presentation at Upcoming American Society of Nephrology Conference
BERKELEY HEIGHTS, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that an
Read more →CRMD▲ +10.1%on this news· ran to +27% by day 3
CorMedix Inc. Reports SECOND Quarter AND SIX MONTH 2022 Financial Results and Provides Business Update Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Berkeley Heights, NJ
Inc. Reports SECOND Quarter AND SIX MONTH 2022 Financial Results and Provides Business Update Call Scheduled for Today at 8:30 a.m. Eastern Time Heights, NJ - August 11, 2022 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing
Read more →CRMDCorMedix Inc. To Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11
BERKELEY HEIGHTS, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will
Read more →CRMDCorMedix to Participate at the JMP Securities Life Sciences Conference
BERKELEY HEIGHTS, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that managem
Read more →CRMDCorMedix Inc. Announces Leadership Updates and Operational Changes
BERKELEY HEIGHTS, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced updates regar
Read more →CRMDCorMedix Inc. Reports First Quarter 2022 Financial Results and Provides Business Update Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ
Inc. Reports First Quarter 2022 Financial Results and Provides Business Update Call Scheduled for Today at 4:30 p.m. Eastern Time NJ - May 12, 2022 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for th
Read more →CRMDCorMedix Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12
BERKELEY HEIGHTS, N.J. , May 03, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will
Read more →CRMDCorMedix Inc. Announces Scientific Advisory Board to Support Commercialization and Pipeline Development
BERKELEY HEIGHTS, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the formati
Read more →CRMDCorMedix Inc. to Present at the 21st Annual Needham Virtual Healthcare Conference
BERKELEY HEIGHTS, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that manage
Read more →CRMDCORMEDIX INC. REPORTS fourth QUARTER and full year 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ
INC. REPORTS fourth QUARTER and full year 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Call Scheduled for Today at 4:30 p.m. Eastern Time NJ - March 29, 2022 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeut
Read more →CRMD▼ -6.6%on this newsshared move
CORMEDIX INC. ANNOUNCES FDA ACCEPTANCE of RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH Berkeley Heights, NJ
INC. ANNOUNCES FDA ACCEPTANCE of RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH Heights, NJ - March 28, 2022 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infect
Read more →CRMDCorMedix Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update on March 29
BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it wil
Read more →CRMDCORMEDIX INC. ANNOUNCES THE APPOINTMENT OF CHIEF EXECUTIVE OFFICER Joseph Todisco to join CorMedix as Chief Executive Officer; Brings significant experience in commercial strategy, business operations and leadership, and
INC. ANNOUNCES THE APPOINTMENT OF CHIEF EXECUTIVE OFFICER Joseph Todisco to join CorMedix as Chief Executive Officer; Brings significant experience in commercial strategy, business operations and leadership, and specialty pharmaceuticals industry NJ - March 17, 2022 - CorMedix
Read more →CRMD▲ +21.4%on this news
CORMEDIX INC. ANNOUNCES RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH Berkeley Heights, NJ
INC. ANNOUNCES RESUBMISSION of NEW DRUG APPLICATION FOR DEFENCATH Heights, NJ - February 28, 2022 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflam
Read more →CRMDCorMedix to Participate in Upcoming January Conferences
BERKELEY HEIGHTS, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedi
Read more →CRMDCORMEDIX INC. REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ
CORMEDIX INC. REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Call Scheduled for Today at 4:30 p.m. Eastern Time Heights, NJ - November 9, 2021 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing ther
Read more →CRMDCorMedix Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9
BERKELEY HEIGHTS, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will
Read more →CRMDCorMedix Inc. Announces Abstracts at Upcoming Conferences Showing Patient Outcomes and Economic Burden of CRBSI
BERKELEY HEIGHTS, N.J., Oct. 20, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the acceptan
Read more →CRMDCorMedix Inc. Announces Executive Leadership Changes
BERKELEY HEIGHTS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced changes to i
Read more →CRMD▼ -22.5%on this news
CorMedix Inc. Announces Regulatory Update
BERKELEY HEIGHTS, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today provided an update wi
Read more →CRMD▼ -22.5%on this news
CORMEDIX INC. ANNOUNCES REGULATORY UPDATE Berkeley Heights, NJ
INC. ANNOUNCES REGULATORY UPDATE NJ - September 7, 2021 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today provided an update w
Read more →CRMDCORMEDIX INC. REPORTS Second QUARTER and six month 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ
INC. REPORTS Second QUARTER and six month 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Call Scheduled for Today at 4:30 p.m. Eastern Time NJ - August 12, 2021 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeut
Read more →CRMDCorMedix Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12
BERKELEY HEIGHTS, N.J., July 28, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will
Read more →CRMDCorMedix, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
Investors with losses are encouraged to contact the firm before September 20, 2021; click here to submit trade information LOS ANGELES, July 27, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of CorMedix, Inc.
Read more →CRMDCorMedix Inc. Completes Sale of $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Program
BERKELEY HEIGHTS, N.J., June 10, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has
Read more →CRMDCorMedix Inc. to Participate in Fireside Chat at the JMP Securities Life Sciences Conference
BERKELEY HEIGHTS, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedi
Read more →CRMDCorMedix Inc. to Present at the Jefferies Virtual Healthcare Conference
BERKELEY HEIGHTS, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix
Read more →CRMDCorMedix Inc. Announces Appointment of Chief Commercial Officer Thomas Nusbickel to join CorMedix as Chief Commercial Officer; Brings significant experience in renal product launches and commercialization Berkeley Height
CorMedix Inc. Announces Appointment of Chief Commercial Thomas Nusbickel to join CorMedix as Chief Commercial Officer; Brings significant experience in renal product launches and commercialization Berkeley Heights, NJ - May 13, 2021 - CorMedix Inc. (Nasdaq: CRMD), a biopharma
Read more →CRMDCorMedix Inc. Reports First Quarter 2021 Financial Results and Provides Business Update Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ
Inc. Reports First Quarter 2021 Financial Results and Provides Business Update Call Scheduled for Today at 4:30 p.m. Eastern Time Heights, NJ - May 13, 2021 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic produc
Read more →CRMDCorMedix Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on May 13
BERKELEY HEIGHTS, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will
Read more →CRMDCorMedix Inc. to Participate at the 7th Annual Truist Securities Life Sciences Summit
BERKELEY HEIGHTS, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMed
Read more →CRMDCORMEDIX HAS MEETING WITH FDA ON DEFENCATH CATHETER LOCK SOLUTION NDA Berkeley Heights, NJ
CORMEDIX HAS MEETING WITH FDA ON DEFENCATH CATHETER LOCK SOLUTION NDA Berkeley Heights, NJ - April 14, 2021 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectiou
Read more →CRMDCorMedix Inc. to Present at the 20th Annual Needham Virtual Healthcare Conference
BERKELEY HEIGHTS, N.J., April 07, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMed
Read more →CRMDCORMEDIX INC. REPORTS fourth QUARTER and full year 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ
INC. REPORTS fourth QUARTER and full year 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Call Scheduled for Today at 4:30 p.m. Eastern Time Heights, NJ - March 30, 2021 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing t
Read more →CRMDCorMedix Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results and Provide a Corporate Update on March 30
BERKELEY HEIGHTS, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it wil
Read more →CRMDCorMedix Approved to Sell $1.3 Million of NOL Tax Benefits Through The New Jersey Economic Development Authority Program
BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has
Read more →CRMDCorMedix Inc. Announces Contract Extension of Liz Masson-Hurlburt as Executive Vice President and Head of Clinical Operations
BERKELEY HEIGHTS, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has
Read more →CRMDCorMedix Inc. to Host Regulatory Update Conference Call
BERKELEY HEIGHTS, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it wil
Read more →CRMDCORMEDIX RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR DEFENCATH CATHETER LOCK SOLUTION Berkeley Heights, NJ
RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR DEFENCATH CATHETER LOCK SOLUTION Berkeley Heights, NJ - March 1, 2021 - CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of i
Read more →CRMDCORMEDIX INC. To begin trading on the Nasdaq Stock exchange Berkeley Heights, NJ
INC. To begin trading on the Nasdaq Stock exchange NJ - January 21, 2021 - CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, to
Read more →CRMDCORMEDIX INC. Announces fda DECISION THAT ADVISORY COMMITTEE MEETING FOR new drug application for defencath IS NOT NEEDED PDUFA date remains
INC. Announces fda DECISION THAT ADVISORY COMMITTEE MEETING FOR new drug application for defencath IS NOT NEEDED NJ - November 18, 2020 - CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the pre
Read more →CRMDCORMEDIX INC. REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ
INC. REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Call Scheduled for Today at 4:30 p.m. Eastern Time NJ - November 5, 2020 - CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic prod
Read more →CRMDCorMedix Appoints Greg Duncan to its Board of Directors Seasoned industry veteran with decades of strategic and commercial leadership experience in the pharmaceutical sector Berkeley Heights, NJ
CorMedix Appoints Greg Duncan to its Board Seasoned industry veteran with decades of strategic and commercial leadership experience in the pharmaceutical sector Berkeley Heights, NJ - November 2, 2020 - CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused
Read more →CRMDCorMedix Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 5
BERKELEY HEIGHTS, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that
Read more →CRMDCorMedix to Participate in BIO Investor Forum Digital
BERKELEY HEIGHTS, N.J., Oct. 08, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that
Read more →CRMDCormedix Appoints Paulo Costa to its Board of Directors Seasoned industry veteran with decades of strategic and commercial leadership experience in the pharmaceutical sector Berkeley Heights, NJ
Cormedix Appoints Paulo Costa to its Seasoned industry veteran with decades of strategic and commercial leadership experience in the pharmaceutical sector Berkeley Heights, NJ - September 17, 2020 - CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on d
Read more →CRMDCorMedix Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
BERKELEY HEIGHTS, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that
Read more →CRMDCORMEDIX INC. Announces fda acceptance for filing and priority review of new drug application for defencath FDA sets PDUFA goal date of
INC. Announces fda acceptance for filing and priority review of new drug application for defencath sets PDUFA goal date of February 28, 2021 the first antibacterial and antifungal catheter lock solution in the US to prevent catheter related infections in hemodialysis NJ - Augu
Read more →CRMDCORMEDIX INC. REPORTS Second QUARTER and six month 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ
INC. REPORTS Second QUARTER and six month 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Call Scheduled for Today at 4:30 p.m. Eastern Time Heights, NJ - August 10, 2020 - CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercia
Read more →CRMDCorMedix Inc. to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 10
BERKELEY HEIGHTS, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that
Read more →CRMDCorMedix Announces Pricing of $20M Public Offering of Common Stock Berkeley Heights, NJ
CorMedix Announces Pricing of $20M Public Offering of Common Stock Berkeley Heights, NJ - July 28, 2020 - CorMedix Inc. (NYSE American: CRMD) (the "Company"), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and tre
Read more →CRMDCorMedix Announces Proposed Public Offering of Common Stock
BERKELEY HEIGHTS, N.J., July 27, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD) (the “Company”), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, annou
Read more →CRMDCORMEDIX INC. REPORTS SUbmission of defencath new drug application Priority Review of NDA Requested Berkeley Heights, NJ
INC. REPORTS SUbmission of defencath new drug application Review of NDA Requested NJ - July 8, 2020 - CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious
Read more →CRMDCORMEDIX INC. ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER Berkeley Heights, NJ
INC. ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER Heights, NJ - May 11, 2020 - CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory dis
Read more →CRMDCORMEDIX INC. REPORTS First QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ
INC. REPORTS First QUARTER 2020 FINANCIAL RESULTS PROVIDES BUSINESS UPDATE Call Scheduled for Today at 4:30 p.m. Eastern Time Heights, NJ - May 11, 2020 - CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic pr
Read more →CRMDCorMedix Hosting KOL Call on Antimicrobial Resistance, Catheter-Related Bloodstream Infections (CRBSIs), and the Potential for Neutrolin
BERKELEY HEIGHTS, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, will host a call with
Read more →CRMDCorMedix Inc. to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 11
BERKELEY HEIGHTS, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that i
Read more →CRMDCorMedix Inc. Announces Contract Extension of Jack Armstrong as Executive Vice President and Head of Technical Operations
BERKELEY HEIGHTS, N.J., April 23, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that
Read more →CRMDCorMedix Completes Sale of $5.5 Million of NOL Tax Benefits through New Jersey Technology Business Tax Certificate Transfer Program Berkeley Heights, NJ
Completes Sale of $5.5 Million of NOL Tax Benefits through New Jersey Technology Business Tax Certificate Transfer Program Heights, NJ - April 22, 2020 - CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic produ
Read more →CRMDCORMEDIX INC. REPORTS fourth QUARTER and full year 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Company in process of submitting New Drug Application (NDA) for Neutrolin for prevention of catheter-related blood st
INC. REPORTS fourth QUARTER and full year 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE in process of submitting New Drug Application (NDA) for Neutrolin for prevention of catheter-related blood stream infections via a rolling review granted by FDA Call Scheduled for Tod
Read more →CRMDCorMedix Inc. to Report Fourth Quarter 2019 Financial Results and Provide a Corporate Update on March 16
BERKELEY HEIGHTS, N.J., March 06, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that
Read more →CRMDCorMedix Inc. Announces FDA Grant of Rolling Review of Neutrolin New Drug Application Berkeley Heights, NJ
CorMedix Inc. Announces FDA Grant of Rolling Review of Neutrolin New Drug Application Berkeley Heights, NJ - February 3, 2020 - CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention
Read more →CRMDCORMEDIX APPROVed TO SELL $5.5 Million OF NOL Tax Benefits Through The New Jersey Economic Development Authority PROGRAM Berkeley Heights, NJ
APPROVed TO SELL $5.5 Million OF NOL Tax Benefits Through The New Jersey Economic Development Authority PROGRAM Berkeley Heights, NJ - February 3, 2020 - CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic pro
Read more →CRMDCorMedix Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update
BERKELEY HEIGHTS, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced finan
Read more →CRMDCorMedix Inc. to Report Third Quarter 2019 Financial Results and Provide a Corporate Update on November 14
BERKELEY HEIGHTS, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that
Read more →CRMDCorMedix Inc. Announces a Change to its Senior Leadership Berkeley Heights, NJ
CorMedix Inc. Announces a Change to its Senior Leadership Berkeley Heights, NJ - November 6, 2019 - CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious a
Read more →CRMDCorMedix Inc. Announces a Change to its Senior Leadership
BERKELEY HEIGHTS, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that
Read more →CRMDMelinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Melinta Therapeutics announced FDA approval for BAXDELA to treat community-acquired bacterial pneumonia based on positive Phase III trial results. However, the company is delaying the commercial launch due to liquidity concerns.
Read more →CRMDCOMPLETES SUCCESSFUL CMC INTERACTION WITH THE FDA
COMPLETES SUCCESSFUL CMC INTERACTION WITH THE FDA NJ - October 16, 2019 - CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, tod
Read more →CRMDCorMedix Completes Successful CMC Interaction with the FDA
BERKELEY HEIGHTS, N.J., Oct. 16, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that
Read more →CRMDCorMedix Inc. to Present at the Cantor 2019 Global Healthcare Conference
BERKELEY HEIGHTS, N.J., Sept. 26, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that
Read more →CRMDCorMedix Inc. Announces Exercises of Outstanding Warrants
BERKELEY HEIGHTS, N.J., Sept. 26, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that
Read more →CRMDCorMedix Inc. to Present at the H.C. Wainwright 21st Annual Global Investment Conference
BERKELEY HEIGHTS, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that
Read more →CRMDCORMEDIX INC. announces EXCHANGE AGREEMENT with its largest investor Berkeley Heights, NJ
INC. announces EXCHANGE AGREEMENT with its largest investor NJ - August 14, 2019 - CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory dis
Read more →CRMDCORMEDIX INC. REPORTS Second QUARTER and six month 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ
INC. REPORTS Second QUARTER and six month 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Call Scheduled for Today at 4:30 p.m. Eastern Time Heights, NJ - August 13, 2019 - CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercia
Read more →CRMDCorMedix Inc. to Report Second Quarter 2019 Financial Results and Provide a Corporate Update on August 13
BERKELEY HEIGHTS, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that
Read more →CRMDCorMedix Presents at FDA Public Meeting on the Limited Population Pathway for Antibacterial and Antifungal Drugs
BERKELEY HEIGHTS, N.J., July 17, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that
Read more →CRMDCORMEDIX RECEIVES ENCOURAGING FDA FEEDBACK ON NEUTROLIN® LOCK-IT-100 DATA Company Completes Phase 3 of Clinical Development Berkeley Heights, NJ –
CORMEDIX RECEIVES ENCOURAGING FDA FEEDBACK ON NEUTROLIN Company Completes Phase 3 of Clinical Development Heights, NJ July 9, 2019 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the preventio
Read more →CRMDCorMedix Announces Publication of Taurolidine Pre-Clinical Oncology Data in “Investigational New Drugs” Journal
BERKELEY HEIGHTS, N.J., July 08, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced publi
Read more →CRMDCorMedix Inc. Set to Join the Russell 2000 Index
BERKELEY HEIGHTS, N.J., June 26, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that
Read more →CRMDCorMedix Inc. to Ring NYSE Closing Bell on Monday, June 10
BERKELEY HEIGHTS, N.J., June 10, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that
Read more →CRMDCorMedix Inc. to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
BERKELEY HEIGHTS, N.J., May 16, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that m
Read more →CRMDCORMEDIX INC. REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ –
CORMEDIX INC. REPORTS FIRST QUARTER 2019 FINANCIAL AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Berkeley Heights, NJ May 13, 2019 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializi
Read more →CRMDCormedix Announces Presentation of LOCK-IT-100 Study Results at National Kidney Foundation Spring 2019 Meeting
BERKELEY HEIGHTS, N.J., May 10, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, is pleased to announce
Read more →CRMDCorMedix Inc. to Report First Quarter 2019 Financial Results and Provide a Corporate Update on May 13
BERKELEY HEIGHTS, N.J., May 06, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that i
Read more →CRMDCorMedix Announces Online Pre-Clinical Abstract at the Upcoming Annual Meeting of American Society of Clinical Oncology
BERKELEY HEIGHTS, N.J., April 22, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced publ
Read more →CRMDCORMEDIX COMPLETES SALE OF $5.4 MILLION OF NOL TAX BENEFITS THROUGH NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY PROGRAM Berkeley Heights, NJ –
CORMEDIX COMPLETES SALE OF $5.4 MILLION OF NOL TAX BENEFITS THROUGH NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY PROGRAM Berkeley Heights, NJ April 17, 2019 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic pro
Read more →CRMDCORMEDIX NOTIFIED OF COMPLIANCE WITH NYSE AMERICAN
CORMEDIX NOTIFIED OF COMPLIANCE WITH NYSE AMERICAN LISTING REQUIREMENTS Berkeley Heights, NJ April 11, 2019 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of inf
Read more →CRMDCORMEDIX CONFIRMS PREVIOUSLY ANNOUNCED ONE-FOR-FIVE REVERSE STOCK SPLIT Berkeley Heights, NJ –
CORMEDIX CONFIRMS PREVIOUSLY ANNOUNCED ONE-FOR-FIVE REVERSE STOCK Berkeley Heights, NJ March 25, 2019 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious
Read more →CRMDCORMEDIX INC. ANNOUNCES APPOINTMENT OF PHOEBE MOUNTS AS EXECUTIVE VICE PRESIDENT AND GENERAL COUNSEL Berkeley Heights, NJ –
CORMEDIX INC. ANNOUNCES APPOINTMENT OF PHOEBE MOUNTS AS EXECUTIVE VICE PRESIDENT AND GENERAL COUNSEL Berkeley Heights, NJ Mar. 21, 2019 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the pre
Read more →CRMDCORMEDIX INC. REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS, ANNOUNCES REVERSE STOCK SPLIT AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Berkeley Heights, NJ &#x
CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS, ANNOUNCES REVERSE STOCK SPLIT AND PROVIDES BUSINESS Conference Call Scheduled for Today at 4:30 p.m. Eastern Berkeley Heights, NJ Mar. 14, 2019 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical
Read more →CRMDCORMEDIX INC. APPOINTS ALAN W. DUNTON, M.D. TO BOARD OF DIRECTORS Berkeley Heights, NJ –
CORMEDIX INC. APPOINTS ALAN W. DUNTON, M.D. TO BOARD OF Berkeley Heights, NJ March 4, 2019 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflam
Read more →CRMDCORMEDIX INC. ANNOUNCES FDA MEETING UPDATE Cleared to Request Approval under LPAD; FDA to Review LOCK-IT-100 Clinical Data Berkeley Heights, NJ –
CORMEDIX INC. ANNOUNCES FDA MEETING UPDATE Cleared to Request Approval under LPAD; FDA to Review LOCK-IT-100 Berkeley Heights, NJ February 14, 2019 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products
Read more →CRMDCORMEDIX INC. ANN OUNCES TOPLINE ANALYSIS OF THE FULL DATA SET OF PHASE 3 LOCK-IT-100 STUDY REINFORCES THE INTERIM RESULTS Berkeley Heights, NJ –
CORMEDIX INC. ANN OUNCES TOPLINE ANALYSIS OF THE FULL DATA SET OF PHASE 3 LOCK-IT-100 STUDY REINFORCES THE INTERIM RESULTS Berkeley Heights, NJ January 30, 2019 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeu
Read more →CRMDCORMEDIX INC. ANNOUNCES HIGHLY STATISTICALLY SIGNIFICANT TOPLINE RESULTS FOR NEUTROLIN® FROM THE INTERIM ANALYSIS OF THE PHASE 3 LOCK-IT-100 STUDY Conference Call today at 4:30 p.m. Eastern Time Berkeley Heights, NJ
CORMEDIX INC. ANNOUNCES HIGHLY STATISTICALLY SIGNIFICANT TOPLINE RESULTS FOR NEUTROLIN FROM THE INTERIM ANALYSIS OF THE PHASE Conference Call today at 4:30 p.m. Eastern Time Berkeley Heights, NJ January 17, 2019 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company
Read more →CRMDCORMEDIX INC. ANNOUNCES RESIGNATION OF MEMBER OF ITS BOARD OF DIRECTORS Berkeley Heights, NJ –
CORMEDIX INC. ANNOUNCES RESIGNATION OF MEMBER OF ITS BOARD OF Berkeley Heights, NJ January 16, 2019 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious a
Read more →CRMDCORMEDIX ANNOUNCES CLOSING OF $7.5 MILLION SENIOR SECURED CONVERTIBLE DEBT FINANCING Berkeley Heights, NJ –
CORMEDIX ANNOUNCES CLOSING OF $7.5 MILLION SENIOR SECURED CONVERTIBLE DEBT FINANCING Berkeley Heights, NJ January 3, 2019 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and tr
Read more →CRMDBlueprint EXHIBIT 9 9.1 CORMEDIX RECEIVES APPROVAL TO SELL $5.4 MILLION OF NOL TAX BENEFITS THROUGH THE NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY PROGRAM Berkeley Heights, NJ –
CORMEDIX RECEIVES APPROVAL TO SELL $5.4 MILLION OF NOL BENEFITS THROUGH THE NEW JERSEY ECONOMIC DEVELOPMENT Berkeley Heights, NJ December 10, 2018 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products
Read more →CRMDCORMEDIX INC. REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call today at 4:30 p.m. Eastern Time Berkeley Heights, NJ –
CORMEDIX INC. REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES Conference Call today at 4:30 p.m. Eastern Time Berkeley Heights, NJ November 14, 2018 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic pro
Read more →CRMDCorMedix Announces NYSE American Acceptance of Plan to Regain Listing Compliance Berkeley Heights, NJ –
CorMedix Announces NYSE American Acceptance of Plan to Regain Listing Compliance Berkeley Heights, NJ August 31, 2018 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatm
Read more →CRMDCORMEDIX INC. REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE LOCK-IT-100 trial results positive; trial halted for efficacy Conference Call today at 4:30 p.m. Eastern Time Berkeley Heights, NJ  
CORMEDIX INC. REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES LOCK-IT-100 trial results positive; trial halted for Conference Call today at 4:30 p.m. Eastern Time Berkeley Heights, NJ August 14, 2018 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focus
Read more →CRMDCORMEDIX INC. ANNOUNCES POSITIVE RESULTS OF ITS NEUTROLIN® PHASE 3 LOCK-IT-100 STUDY BASED ON RECOMMENDATION BY INDEPENDENT DATA SAFETY MONITORING BOARD Statistical Significance Achieved at Interim Analysis Berkeley
CORMEDIX INC. ANNOUNCES POSITIVE RESULTS OF ITS NEUTROLIN LOCK-IT-100 STUDY BASED ON RECOMMENDATION BY INDEPENDENT SAFETY MONITORING BOARD Statistical Significance Achieved at Interim Analysis Berkeley Heights, NJ July 25, 2018 CorMedix Inc. (NYSE American: CRMD), a biopharm
Read more →CRMDCORMEDIX INC. COMPLETES REVIEW AND SOURCE VERIFICATION OF PHASE 3 LOCK-IT 100 DATA FOR NEUTROLIN ® The Company anticipates Data Safety Monitoring Board Review in July 2018 Berkeley Heights, NJ –
CORMEDIX INC. COMPLETES REVIEW AND SOURCE VERIFICATION OF PHASE 3 LOCK-IT 100 DATA FOR The Company anticipates Data Safety Monitoring Board Review in July Berkeley Heights, NJ June 20, 2018 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing
Read more →CRMDCORMEDIX INC. RECEIVES A CONTINUED LISTING STANDARD NOTICE FROM THE NYSE AMERICAN Berkeley Heights, NJ –
CORMEDIX INC. RECEIVES A CONTINUED LISTING STANDARD NOTICE FROM THE Berkeley Heights, NJ June 19, 2018 American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory d
Read more →CRMDCORMEDIX INC. REPORTS PROGRESS ON LOCK-IT 100 DATA REVIEW AND APPOINTS PAUL CHEW AS CONSULTANT ADVISOR CMO ● More than 75% of key data for Neutrolin ® Phase 3 LOCK-IT 100 reviewed and source-verified for pre-
CORMEDIX INC. REPORTS PROGRESS ON LOCK-IT 100 DATA REVIEW AND APPOINTS PAUL CHEW AS CONSULTANT ADVISOR CMO More than 75% of key data for Phase 3 LOCK-IT 100 reviewed and source-verified for pre-planned Dr. Paul Chew, cardiologist and seasoned biopharmaceutical executive app
Read more →CRMDCORMEDIX INC. REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ● Anticipate Data Safety Monitoring Board review of interim analysis in July 2018; review was triggered in December 2017 with 28 c
CORMEDIX INC. REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES Anticipate Data Safety Monitoring Board review of interim analysis in July 2018; review was triggered in December 2017 with 28 confirmed cases of catheter-related bloodstream infections (CRBSIs) identified in
Read more →CRMDCorMedix Revises Timeline and Announces Changes to Lock-It-100 Study Management Berkeley Heights, NJ –
CorMedix Revises Timeline and Announces Changes to Lock-It-100 Berkeley Heights, NJ April 27, 2018 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious an
Read more →CRMDCORMEDIX INC. REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Recent Corporate and Clinical Highlights: ● 28 c
CORMEDIX INC. REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call Scheduled for Today at 4:30 p.m. Eastern Recent Corporate and Clinical Highlights: cases of catheter-related bloodstream infections (CRBSIs) identified by t
Read more →CRMDCorMedix Inc. Provides Update on its Financing Plans in Connection with its Ongoing LOCK-IT 100 Clinical Study Berkeley Heights, NJ –
CorMedix Inc. Provides Update on its Financing Plans in Connection with its Ongoing LOCK-IT 100 Clinical Study Berkeley Heights, NJ February 27, 2018 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic product
Read more →CRMDCorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma Berkeley Heights, NJ –
CorMedix Inc. Granted Orphan Drug Designation for Taurolidine for Treatment of Neuroblastoma Berkeley Heights, NJ February 26, 2018 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the preventi
Read more →CRMDCorMedix Inc. Achieves Target Number of Events in Its LOCK-IT-100 Study of Neutrolin® for Interim Efficacy Analysis Berkeley Heights, NJ – February , 2018 – CorMedix Inc. (NYSE American: CRMD), a bioph
CorMedix Inc. Achieves Target Number of Events in Its LOCK-IT-100 Study of Neutrolin for Interim Efficacy Analysis Berkeley Heights, NJ February , 2018 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic produ
Read more →CRMDCorMedix Inc. Announces Common Stock Purchase by Company Directors and Executive Management Team Berkeley Heights, NJ –
CorMedix Inc. Announces Common Stock Purchase by Company Directors and Executive Management Team Berkeley Heights, NJ November 20, 2017 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the pre
Read more →CRMDCorMedix Inc. Enters into $5 million Combined Securities Purchase and Backstop Agreement with Existing Investor Berkeley Heights, NJ –
CorMedix Inc. Enters into $5 million Combined Securities Purchase and Backstop Agreement with Existing Investor Berkeley Heights, NJ November 9, 2017 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic product
Read more →CRMDCorMedix Inc. Reports Third Quarter Financial Results and Provides Business Update Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Recent Corporate and Clinical Highlights: ● Executed $5 million comb
CorMedix Inc. Reports Third Quarter Financial Results and Provides Conference Call Scheduled for Today at 4:30 p.m. Eastern Recent Corporate and Clinical Highlights: combined Securities Purchase and Backstop Agreement advance Phase 3 LOCK-IT 100 clinical study of Neutrolin ,
Read more →CRMDCorMedix Inc. Reports Second Quarter Financial Results and Provides Business Update Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Recent Corporate and Clinical Highlights: ● Implemented several key
CorMedix Inc. Reports Second Quarter Financial Results and Provides Conference Call Scheduled for Today at 4:30 p.m. Eastern Recent Corporate and Clinical Highlights: key FDA-agreed changes to the LOCK-IT-100 trial designed to enhance event capture and significantly reduced t
Read more →CRMDCorMedix Inc. Appoints Gary Gelbfish, M.D., to Board of Directors Current Director Myron Kaplan Elected Chairman of the Board Bedminster, NJ –
CorMedix Inc. Appoints Gary Gelbfish, M.D., to Board of Current Director Myron Kaplan Elected Chairman of the Bedminster, NJ August 7, 2017 CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the
Read more →CRMDCorMedix Inc. Provides Update on Neutrolin ® Ongoing Phase 3 Clinical Trial Following Favorable FDA Correspondence Bedminster, NJ –
CorMedix Inc. Provides Update on Neutrolin Ongoing Phase 3 Following Favorable FDA Correspondence Bedminster, NJ August 2, 2017 CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and t
Read more →CRMDCorMedix Inc. Provides Comprehensive Pipeline Update During Research and Development Day Live Webcast Today
CorMedix Inc. Provides Comprehensive Pipeline Update During Research and Development Day Live Webcast Today, July 12, 2017, beginning at 8:30am Bedminster, NJ July 12, 2017 CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing
Read more →CRMDCorMedix Inc. Appoints Mehmood Khan, M.D. and Steven Lefkowitz to its Board of Directors Gary Gelbfish, M.D. Appointed as Observer to the Company's Board of Directors by Elliott Management Bedminster, NJ –
CorMedix Inc. Appoints Mehmood Khan, M.D. and Steven Lefkowitz to its Board of Directors Gary Gelbfish, M.D. Appointed as Observer to the Company's Board of Directors by Elliott Management Bedminster, NJ June 26, 2017 CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical compa
Read more →CRMDFDA approves new antibiotic for skin infections
The FDA has approved Melinta Therapeutics' Baxdela, a new antibiotic for serious skin infections, providing an additional treatment option against antimicrobial-resistant pathogens. The approval follows successful Phase 3 studies, although the drug carries warnings for potential serious side effects.
Read more →CRMDCorMedix Inc. Announces Changes to Board of Directors Bedminster, NJ –
CorMedix Inc. Announces Changes to Board of Directors Bedminster, NJ June 12, 2017 CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseas
Read more →CRMDCorMedix Inc. Reports First Quarter Financial Results and Provides Business Update Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Recent Corporate and Clinical Highlights: ● Completed independent Da
CorMedix Inc. Reports First Quarter Financial Results and Provides Conference Call Scheduled for Today at 4:30 p.m. Eastern Recent Corporate and Clinical Highlights: independent Data and Safety Monitoring Board (DSMB) review for Phase 3 LOCK-IT 100 study of Neutrolin in hemod
Read more →CRMDCorMedix Inc. Announces Closing of Public Offering of Common Stock and Warrants and Underwriter's Exercise In Full of Over-Allotment Option Bedminster, NJ –
CorMedix Inc. Announces Closing of Public Offering of Common Stock and Warrants and Underwriter's Exercise In Full of Over-Allotment Option Bedminster, NJ May 3, 2017 CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therap
Read more →CRMDCorMedix Inc. Announces $10 Million Underwritten Public Offering Bedminster, NJ –
CorMedix Inc. Announces $10 Million Underwritten Public Bedminster, NJ April 27, 2017 CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory dis
Read more →CRMDCorMedix Inc. Reports Update on Neutrolin ® Phase 3 LOCK-IT 100 Clinical Trial Bedminster, NJ –
CorMedix Inc. Reports Update on Neutrolin Phase LOCK-IT 100 Clinical Trial Bedminster, NJ April 20, 2017 CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious
Read more →CRMDCorMedix Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Recent Corporate and Clinical Highlights: ● Surp
CorMedix Inc. Reports Fourth Quarter and Full Year Financial Results and Provides Business Update Conference Call Scheduled for Today at 8:30 a.m. Eastern Recent Corporate and Clinical Highlights: enrollment midpoint in pivotal Phase 3 LOCK-IT 100 study of Neutrolin in hemod
Read more →CRMDCorMedix Inc. Announces New Appointments to Senior Leadership Team Robert W. Cook, International Biopharma Finance Expert, Appointed Chief Financial Officer Judith R. Abrams, M.D., Clinical Development Veteran, Appointed
CorMedix Inc. Announces New Appointments to Senior Leadership Robert W. Cook, International Biopharma Finance Expert, Appointed Chief Financial Officer Judith R. Abrams, M.D., Clinical Development Veteran, Appointed Chief Medical Officer Bedminster, NJ February 1, 2017 CorMe
Read more →CRMDCorMedix Inc. Reports Third Quarter 2016 Financial Results and Provides Business Updates Conference Call Today at 4:30 p.m. Eastern Time Bedminster, NJ –
Inc. Reports Third Quarter 2016 Financial Results and Provides Conference Call Today at 4:30 p.m. Eastern Time Bedminster, NJ November 10, 2016 CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the
Read more →CRMDCorMedix Inc. Appoints Khoso Baluch as Chief Executive Officer Bedminster, NJ – October 3 , 2016 – CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing thera
CorMedix Inc. Appoints Khoso Baluch as Chief Executive Bedminster, NJ October 3, 2016 biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, announced today that it has
Read more →CRMDCorMedix Inc. Reports Second Quarter 2016 Financial Results and Provides Business Updates Conference Call Today at 9:00 a.m. Eastern Time Bedminster, NJ –
CorMedix Inc. Reports Second Quarter 2016 Financial Results and Provides Business Updates Conference Call Today at 9:00 a.m. Eastern Time Bedminster, NJ August 5, 2016 CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeu
Read more →CRMDCorMedix Secures First Research Collaboration in the Medical Device Space with Luna Innovations Inc. Bedminster, NJ –
CorMedix Secures First Research Collaboration in the Medical Device Space with Luna Innovations Inc. Bedminster, NJ June 29, 2016 CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and tr
Read more →CRMDCorMedix Inc. Reports First Quarter 2016 Financial Results Conference Call Today at 9:00 a.m. Eastern Time Corporate Highlights: Continued to enroll patients and engage clinical sites for Phase 3 LOCK-IT 100 study Secure
CorMedix Inc. Reports First Quarter 2016 Financial Results Conference Call Today at 9:00 a.m. Eastern Time Corporate Highlights: Continued to enroll patients and engage clinical sites for Phase 3 LOCK-IT 100 study Secured exclusive research licenses to NanoProteagen's nano
Read more →CRMDCorMedix Appoints Myron Kaplan to Board of Directors Bedminster, NJ –
CorMedix Appoints Myron Kaplan to Board of Directors Bedminster, NJ May 2, 2016 CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announ
Read more →CRMDCorMedix Inc. Reports Fourth Quarter and Full Year 2015 Financial Results Conference Call Scheduled for Today at 9:00 a.m. ET 2015 Highlights: ● Initiated pivotal Phase 3 “LOCK-IT 100” study of Neutr
CorMedix Inc. Reports Fourth Quarter and Full Year 2015 Conference Call Scheduled for Today at 9:00 a.m. ET Initiated pivotal Phase 3 LOCK-IT 100 study of Neutrolin in hemodialysis patients Completed landmark Neutrolin Usage Monitoring Program (NUMP) Awarded FDA Fast Track an
Read more →CRMDCorMedix Inc. 2015 Year in Review and 2016 Objectives Dear Shareholders and Investors, Bedminster, NJ
CorMedix Inc. 2015 Year in Review and 2016 Objectives Dear Shareholders and Investors, Bedminster, NJ - February 22, 2016 - CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment o
Read more →CRMDCorMedix's CEO Randy Milby Interviewed by The Life Sciences Report
SAN FRANCISCO, CA--(Marketwired - February 12, 2016) - Patients on dialysis and cancer patients with indwelling catheters live with the possibility of contracting drug-resistant infections that can become more life threatening than their primary diseases. CorMedix Inc. (NYSE MKT
Read more →CRMDCorMedix Announces Enrollment and Dosing of First Patient in Phase 3 Neutrolin Trial in Hemodialysis BEDMINSTER, N.J.
CorMedix Announces Enrollment and Dosing of First Patient in Phase 3 Neutrolin Trial in Hemodialysis BEDMINSTER, N.J., Dec. 14, 2015 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the
Read more →CRMDCorMedix Inc. Announces Janet M. Dillione will join Board of Directors Bedminster, N.J.
CorMedix Inc. Announces Janet M. Dillione will join Board of Directors Bedminster, N.J., August 6, 2015 -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and
Read more →CRMDCorMedix Inc. Announces Decision to Initiate Neutrolin Phase 3 Clinical Study --Strategic Process Now Focused On Identifying Product Development & Commercialization Partners --Seeking Successor CEO to Drive Clinical Deve
CorMedix Inc. Announces Decision to Initiate Neutrolin Phase 3 Clinical Study --Strategic Process Now Focused On Identifying Product Development & Commercialization Partners --Seeking Successor CEO to Drive Clinical Development --To Report Second Quarter 2015 Results --Compa
Read more →CRMDCorMedix Inc. to Join Russell Global and Russell 3000 Indexes BEDMINSTER, N.J.
CorMedix Inc. to Join Russell Global and Russell 3000 Indexes BEDMINSTER, N.J., June 22, 2015 -- CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infe
Read more →CRMDCorMedix Inc. Receives Positive Feedback from FDA for Neutrolin Clinical Trial Protocol for Oncology Patients BEDMINSTER, N.J.
CorMedix Inc. Receives Positive Feedback from FDA for Neutrolin Clinical Trial Protocol for Oncology BEDMINSTER, N.J., June 17, 2015 -- CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention
Read more →CRMDCorMedix Presents Data from Neutrolin Post Marketing Surveillance Study At Two Medical Conferences BEDMINSTER, N.J.
CorMedix Presents Data from Neutrolin Post Marketing Surveillance Study At Two Medical Conferences BEDMINSTER, N.J., April 23, 2015 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the
Read more →CRMDCorMedix Institutes Program to Reduce Neutrolin Cost of Goods; Reports on Strategic Review Process Managed by Evercore BEDMINSTER, N.J.
CorMedix Institutes Program to Reduce Neutrolin Cost of Goods; Reports on Strategic Review Process Managed by Evercore BEDMINSTER, N.J., April 9, 2015 -- CorMedix Inc. (NYSE MKT: CRMD), a global biopharmaceutical company focused on developing and commercializing therapeutic pro
Read more →CRMDCorMedix Inc. Provides Multiple Strategic Business Updates -CorMedix Inc. Engages Evercore as Financial Advisor to Explore Strategic Alternatives to Maximize Shareholder Value- -Elliott Management Provides Backstop Finan
CorMedix Inc. Provides Multiple Strategic Business Updates -CorMedix Inc. Engages Evercore as Financial Advisor to Explore Strategic Alternatives to Maximize Shareholder Value- -Elliott Management Provides Backstop Financing Commitment and Granted Right to Appoint Two Increment
Read more →CRMDFDA Grants QIDP Designation to Neutrolin , CorMedix Inc.'s Lead Product Candidate in the U.S. CorMedix is Developing Neutrolin for the Prevention of Catheter Related Bloodstream Infections and Maintenance of Catheter Pat
FDA Grants QIDP Designation to Neutrolin , CorMedix Inc.'s Lead Product Candidate in the U.S. CorMedix is Developing Neutrolin for the Prevention of Catheter Related Bloodstream Infections and Maintenance of Catheter Patency in Hemodialysis, Oncology and Intensive Care BRIDGEWA
Read more →CRMDCorMedix Inc. Receives Fast Track Designation for Neutrolin BRIDGEWATER, N.J.
CorMedix Inc. Receives Fast Track Designation for Neutrolin BRIDGEWATER, N.J., January 15, 2015 -- CorMedix Inc. (NYSE MKT: CRMD), a specialty pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal
Read more →CRMDCorMedix Inc. 2014 Year in Review Dear Shareholders and Investors, CorMedix Inc. is providing a review of our 2014 business accomplishments and an outline our 2015 company objectives. Over the last couple of years, CorMe
CorMedix Inc. 2014 Year in Review Dear Shareholders and Investors, CorMedix Inc. is providing a review of our 2014 business accomplishments and an outline our 2015 company objectives. Over the last couple of years, CorMedix has evolved into a commercial stage specialty pharmac
Read more →CRMDCorMedix Inc. Finalizes First Middle East Neutrolin Sales/Distribution Agreement in the Kingdom of Saudi Arabia BRIDGEWATER, N.J.
CorMedix Inc. Finalizes First Middle East Neutrolin Sales/Distribution Agreement in the Kingdom of Saudi Arabia BRIDGEWATER, N.J., December 23, 2014 -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the
Read more →CRMDNeutrolin Label Expansion Approved in Germany BRIDGEWATER, N.J.
Neutrolin Label Expansion Approved in Germany BRIDGEWATER, N.J., December 3, 2014 -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease,
Read more →CRMD27/14 CorMedix Receives Approval from FDA to Initiate a Clinical Trial for Neutrolin in the
CorMedix Receives Approval from FDA to Initiate a Clinical Trial for Neutrolin in the US BRIDGEWATER, N.J., October 24, 2014 -- CorMedix Inc. (NYSE MKT: CRMD) is pleased to announce today that the United States Food and Drug Administration (FDA) has reviewed its Investigational
Read more →CRMDCorMedix Announces FDA IND Filing for Neutrolin in United States BRIDGEWATER, N.J.
CorMedix Announces FDA IND Filing for Neutrolin in United States BRIDGEWATER, N.J., September 25, 2014 -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal an
Read more →CRMDNeutrolin Label Expansion Approved for the European Union BRIDGEWATER, N.J.
Neutrolin Label Expansion Approved for the European Union BRIDGEWATER, N.J., September 22, 2014 -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectio
Read more →CRMDCorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification BRIDGEWATER, N.J.
CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification BRIDGEWATER, N.J., September 16, 2014 /PRNewswire/ -- CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializ
Read more →CRMDFDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol Signs Business Collaboration in South Korea with Wonik Corporation Second Quarter 2014 Conference Call Friday August 15 th at 9:00 am BRIDGEWATER, N.J.
FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol Signs Business Collaboration in South Korea with Wonik Corporation Second Quarter 2014 Conference Call Friday August 15th at 9:00 am BRIDGEWATER, N.J., August 14, 2014 -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical
Read more →CRMDCorMedix, Inc. Finalizes Pivotal Phase 3 Study Protocol for
CorMedix, Inc. Finalizes Pivotal Phase 3 Study Protocol for FDA BRIDGEWATER, N.J., June 23, 2014 -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infecti
Read more →CRMDCorMedix Notified of NYSE MKT Listing Deficiency BRIDGEWATER, N.J.
CorMedix Notified of NYSE MKT Listing Deficiency BRIDGEWATER, N.J., May 23, 2014 /PRNewswire/ -- CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal d
Read more →CRMDCorMedix Inc. to Announce First Quarter 2014 Results on
CorMedix Inc. to Announce First Quarter 2014 Results on May 15, 2014 Host Conference Call at 9 am on Friday, May 16, 2014 Bridgewater, New Jersey, May 13, 2014 (PRNewswire) - CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), a specialty pharmaceutical company focused on developing a
Read more →CRMDCorMedix Inc. Welcomes Additional Board Members BRIDGEWATER, N.J.
CorMedix Inc. Welcomes Additional Board Members BRIDGEWATER, N.J., April 7, 2014 -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease, tod
Read more →CRMDCorMedix Inc. Announces Registered Direct Offering BRIDGEWATER, N.J.
CorMedix Inc. Announces Registered Direct Offering BRIDGEWATER, N.J., March 4, 2014 -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious disease,
Read more →CRMDInvestor Contact: The Ruth Group Lee Roth Tel: 646-536-7012 lroth@theruthgroup.com Media Contact: The Ruth Group Melanie Sollid-Penton Tel: 646-536-7023 msollid@theruthgroup.com CorMedix Expands Neutrolin Sales with Midd
CorMedix Expands Neutrolin Sales with Middle East Distribution Agreements Company Establishes Sales and Marketing Oversight Committee for Neutrolin Commercialization BRIDGEWATER, N.J., Jan. 13, 2014 - CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on develop
Read more →CRMDInvestor Contact: The Ruth Group Lee Roth Tel: 646-536-7012 lroth@theruthgroup.com Media Contact: The Ruth Group Melanie Sollid-Penton Tel: 646-536-7023 msollid@theruthgroup.com CorMedix Awarded European Patent for Neutr
Investor Contact: The Ruth Group Lee Roth Tel: 646-536-7012 lroth@theruthgroup.com Media Contact: The Ruth Group Melanie Sollid-Penton Tel: 646-536-7023 msollid@theruthgroup.com CorMedix Awarded European Patent for Neutrolin BRIDGEWATER, N.J., January 10, 2014 - CorMedix Inc
Read more →CRMDCorMedix Inc. to Raise $2,000,000 in Follow On Offering BRIDGEWATER, N.J.
CorMedix Inc. to Raise $2,000,000 in Follow On Offering BRIDGEWATER, N.J., January 8, 2014 -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal and infectious di
Read more →CRMDInvestor Contact: The Ruth Group Lee Roth Tel: 646-536-7012 lroth@theruthgroup.com Media Contact: The Ruth Group Melanie Sollid-Penton Tel: 646-536-7023 msollid@theruthgroup.com CorMedix Receives Minutes from Neutrolin P
Investor Contact: The Ruth Group Lee Roth Tel: 646-536-7012 lroth@theruthgroup.com Media Contact: The Ruth Group Melanie Sollid-Penton Tel: 646-536-7023 msollid@theruthgroup.com CorMedix Receives Minutes from Neutrolin Pre-IND Meeting with FDA BRIDGEWATER, N.J., Dec. 23,
Read more →CRMDInvestor Contact: The Ruth Group Lee Roth Tel: 646-536-7012 lroth@theruthgroup.com Media Contact: The Ruth Group Melanie Sollid-Penton Tel: 646-536-7023 msollid@theruthgroup.com CorMedix Announces First Sales of Neutroli
Investor Contact: The Ruth Group Lee Roth Tel: 646-536-7012 lroth@theruthgroup.com Media Contact: The Ruth Group Melanie Sollid-Penton Tel: 646-536-7023 msollid@theruthgroup.com CorMedix Announces First Sales of Neutrolin in the European Union BRIDGEWATER, N.J., December
Read more →CRMDDRIVES EVERYTHING WE DO Company Overview NYSE MKT: CRMD December 2013 2013 CorMedix 2 Forward Looking Statements This presentation contains certain statements that constitute forward-looking statements within the meaning
DRIVES EVERYTHING WE DO Forward Looking Statements This presentation contains certain statements that constitute forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and
Read more →CRMDCorMedix Inc. Closes $3,000,000 Preferred Stock Offerings As a result, meets NYSE MKT continued listing requirements Conference Call Planned for Mid-November Bridgewater, New Jersey
CorMedix Inc. Closes $3,000,000 Preferred Stock Offerings As a result, meets NYSE MKT continued listing requirements Conference Call Planned for Mid-November Bridgewater, New Jersey, October 23, 2013 (PRNewswire) - CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focus
Read more →CRMDCorMedix Reports Receipt of European Patent Office Decision to Allow Prosl Patent to Proceed in European Union Bridgewater, New Jersey
CorMedix Reports Receipt of European Patent Office Decision to Allow Prosl Patent to Proceed in European Union Bridgewater, New Jersey, September 5, 2013 (PR Newswire) - CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializi
Read more →CRMDNYSE MKT: CRMD August 2013 Company Overview 2013 CorMedix Inc 2 Forward Looking Statements This presentation contains certain statements that constitute forward-looking statements within the meaning of the federal securi
Forward Looking Statements This presentation contains certain statements that constitute forward-looking statements within the meaning of the federal securities laws. Statements that are not historical facts, including statements about our beliefs and expectations, are forward
Read more →CRMDCorMedix Reports Second Quarter 2013 Results Also Reports Board and Officer Appointments Company to Host Conference Call at 9:00 a.m. EDT
CorMedix Reports Second Quarter 2013 Results Also Reports Board and Officer Appointments Company to Host Conference Call at 9:00 a.m. EDT, August 15, 2013 Bridgewater, New Jersey, August 14, 2013 (PR Newswire) - CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), a pharmaceutical com
Read more →CRMDCorMedix Granted Extension of NYSE MKT Listing Bridgewater, New Jersey
CorMedix Granted Extension of NYSE MKT Bridgewater, New Jersey, July 15, 2013 (PRNewswire) - CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal dis
Read more →CRMDCorMedix Receives CE Mark for Neutrolin Catheter Lock Solution Drug - Device Shown to Prevent Catheter Related Bloodstream Infections and Maintain Catheter Patency, a Major Health Issue for Patients Requiring Long-term C
CorMedix Receives CE Mark for Neutrolin Catheter Lock Solution Shown to Prevent Catheter Related Bloodstream Infections and Maintain Catheter Patency, a Major Health Issue for Patients Requiring Long-term Catheter Use - - Company to Hold Investor Conference Call on July 8th
Read more →CRMDCorMedix Notified of NYSE MKT Listing Deficiency Also Defers License Milestone Payment Bridgewater, New Jersey
CorMedix Notified of NYSE MKT Listing Also Defers License Milestone Payment Bridgewater, New Jersey, April 11, 2013 (Business Wire) - CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the p
Read more →CRMDCORMEDIX REPORTS YEAR END 2012 FINANCIAL RESULTS Bridgewater, New Jersey
CORMEDIX REPORTS YEAR END 2012 FINANCIAL Bridgewater, New Jersey, March 27, 2013 (Business Wire) - CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardioren
Read more →CRMDCorMedix Signs Sales and Marketing Agreement
CorMedix Signs Sales and Marketing Agreement Bolsters Commercial Management Team to Neutrolin Catheter Lock Solution European marketing plans for lead product; prepares for initiation of U.S. regulatory registration process - Bridgewater, NJ, January 15, 2013 - CorMedix Inc
Read more →CRMDCorMedix Announces Changes in Executive Team Bridgewater, New Jersey
CorMedix Announces Changes in Executive Bridgewater, New Jersey, December 24, 2012 (Business Wire) - CorMedix Inc. ("CorMedix") (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardio
Read more →CRMDCorMedix: Final Closing of 2012 Financing Bridgewater, New Jersey
CorMedix: Final Closing of 2012 Financing Bridgewater, New Jersey, November 14, 2012 (Business Wire) - CorMedix Inc. ("CorMedix") (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of card
Read more →CRMDCorMedix: Initial Close on Financing and Extension Granted to Regain Compliance with NYSE Amex Listing Standards Bridgewater, New Jersey
CorMedix: Initial Close on Financing and Extension Granted to Regain Compliance with NYSE Amex Listing Standards Bridgewater, New Jersey, September 25, 2012 (Business Wire) - CorMedix Inc. ("CorMedix") (NYSE Amex: CRMD), a pharmaceutical company focused on developing and com
Read more →CRMDCorMedix: Granted Extension of NYSE Amex Listing Compliance Plan Approved Bridgewater, New Jersey
CorMedix: Granted Extension of NYSE Amex Compliance Plan Approved Bridgewater, New Jersey, July 2, 2012 (Business Wire) - CorMedix Inc. ("CorMedix") (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention a
Read more →CRMDCorMedix Provides an Update on CE Marking Process for Neutrolin in the EU Commercial Launch Targeted for 4Q2012/1Q2013 Bridgewater, New Jersey
CorMedix Provides an Update on CE Marking Process for Neutrolin in the EU Commercial Launch Targeted for 4Q2012/1Q2013 Bridgewater, New Jersey, June 14, 2012 (Business Wire) - CorMedix Inc. ("CorMedix") (NYSE Amex: CRMD), a pharmaceutical company focused on developing and co
Read more →CRMDCorMedix Strengthens Management Team with Addition of Randy Milby as Chief Operating Officer. Brian Lenz resigns as COO and CFO to pursue an opportunity with another life sciences company. Richard M. Cohen, Interim CEO,
CorMedix Strengthens Management Team with Addition of Randy Milby as Chief Operating Officer. Brian Lenz resigns as COO and CFO to pursue an opportunity with another life sciences company. Richard M. Cohen, Interim CEO, will add title of Interim CFO. Bridgewater, New Jersey
Read more →CRMDCORMEDIX RECEIVES NYSE AMEX NOTICE OF DELISTING FOR NON-COMPLIANCE Bridgewater, NJ
CORMEDIX RECEIVES NYSE AMEX NOTICE OF DELISTING FOR NON-COMPLIANCE Bridgewater, NJ: April 24, 2012: CorMedix Inc. ("CorMedix") (NYSE Amex: CRMD), is a development stage pharmaceutical and medical device company that seeks to in-license, develop and commercialize therapeutic p
Read more →CRMDCorMedix Licenses New Technology to Prevent Infection and Clots in Central Venous Catheters
SUMMIT, N.J., Feb. 6, 2008 (PRIME NEWSWIRE) -- CorMedix Inc., a New York-area biopharmaceutical company, announced today that it had acquired exclusive worldwide rights to develop, manufacture and market Neutrolin(r), a liquid that "locks" a patient's central venous catheter (CVC
Read more →CRMDCorMedix Enlists World-Class Panel to Advise On Cardiorenal Medicine
SUMMIT, N.J., Jan. 8, 2008 (PRIME NEWSWIRE) -- CorMedix Inc., a biopharmaceutical company, today announced that it had established an advisory panel of world-renowned physicians with special expertise in cardiorenal disease -- the epidemic intersection of cardiovascular disease a
Read more →CRMDCorMedix Studies Show That Removing 'Toxic' Iron Could Slow Progression of Chronic Kidney Disease
SAN FRANCISCO, Nov. 2, 2007 (PRIME NEWSWIRE) -- In the first two proof-of-concept studies in humans, CorMedix Inc. has shown that deferiprone -- an iron-trapping drug -- could become a major new therapy to slow the progression of chronic kidney disease (CKD) and its metabolic and
Read more →Competitive Position
How CRMD ranks across every disease it competes inCompetitive Position is a premium feature
See how CRMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial